

Table 19.1
Non-Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2014 With up to Five Joinpoints, 1992-2014 With up to Four Joinpoints,
Both Sexes by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2005-14	2010-14
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2014</u>														
All Races	1975-91	3.6*	1991-07	0.7*	2007-14	-0.6							-0.3	-0.6
White	1975-90	3.8*	1990-07	0.8*	2007-14	-0.7*							-0.3	-0.7*
Black	1975-95	4.4*	1995-14	0.2									0.2	0.2
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2014</u>														
All Races	1992-09	0.5*	2009-14	-1.0									-0.3	-1.0
White	1992-07	0.7*	2007-14	-0.6									-0.3	-0.6
Black	1992-97	4.0*	1997-00	-4.3	2000-04	3.8	2004-14	-0.6					-0.6	-0.6
<u>SEER 9 Observed Incidence^a, 1975-2014</u>														
All Races	1975-91	3.6*	1991-08	0.7*	2008-14	-1.2*							-0.6*	-1.2*
White	1975-90	3.8*	1990-07	0.8*	2007-14	-1.1*							-0.7*	-1.1*
Black	1975-95	4.5*	1995-14	0.0									0.0	0.0
<u>SEER 13 Observed Incidence^b, 1992-2014</u>														
All Races	1992-09	0.5*	2009-14	-1.5*									-0.6	-1.5*
White	1992-09	0.6*	2009-14	-1.5*									-0.6	-1.5*
White NH ^{ef}	1992-07	0.8*	2007-14	-1.0*									-0.6*	-1.0*
Black	1992-97	4.0*	1997-00	-4.3	2000-04	4.0	2004-14	-1.0*					-1.0*	-1.0*
Black NH ^{ef}	1992-97	3.8*	1997-00	-4.2	2000-04	4.0	2004-14	-0.8*					-0.8*	-0.8*
API ^e	1992-14	0.2											0.2	0.2
AI/AN ^{eg}	1992-14	1.3											1.3	1.3
Hispanic ^f	1992-14	0.4*											0.4*	0.4*
<u>U.S. Cancer Mortality^c, 1975-2014</u>														
All Races	1975-91	2.5*	1991-97	1.6*	1997-06	-3.1*	2006-14	-2.2*					-2.3*	-2.2*
White	1975-91	2.5*	1991-97	1.6*	1997-06	-3.1*	2006-14	-2.2*					-2.3*	-2.2*
Black	1975-96	2.7*	1996-14	-2.3*									-2.3*	-2.3*
<u>U.S. Cancer Mortality^c, 1992-2014</u>														
All Races	1992-97	1.7*	1997-06	-3.1*	2006-14	-2.2*							-2.3*	-2.2*
White	1992-97	1.7*	1997-06	-3.1*	2006-14	-2.2*							-2.3*	-2.2*
White NH ^{ef}	1992-97	1.9*	1997-06	-3.1*	2006-14	-2.2*							-2.3*	-2.2*
Black	1992-96	2.5	1996-14	-2.3*									-2.3*	-2.3*
Black NH ^{ef}	1992-96	2.9	1996-14	-2.2*									-2.2*	-2.2*
API ^e	1992-14	-1.9*											-1.9*	-1.9*
AI/AN ^{eg}	1992-14	-0.8											-0.8	-0.8
Hispanic ^f	1992-97	3.0*	1997-03	-3.6*	2003-14	-1.3*							-1.3*	-1.3*

Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute. (<https://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero ($p < .05$).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.2
Non-Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2014 With up to Five Joinpoints, 1992-2014 With up to Four Joinpoints,
Males by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2005-14	2010-14
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2014</u>														
All Races	1975-91	4.3*	1991-14	0.3*									0.3*	0.3*
White	1975-90	4.4*	1990-08	0.6*	2008-14	-0.6							-0.2	-0.6
Black	1975-94	5.5*	1994-14	-0.3									-0.3	-0.3
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2014</u>														
All Races	1992-14	0.2											0.2	0.2
White	1992-95	2.7	1995-98	-2.1	1998-09	0.8*	2009-12	-2.1	2012-14	1.8			0.1	-0.2
Black	1992-14	-0.1											-0.1	-0.1
<u>SEER 9 Observed Incidence^a, 1975-2014</u>														
All Races	1975-91	4.2*	1991-10	0.4*	2010-14	-1.6							-0.5	-1.6
White	1975-90	4.4*	1990-08	0.6*	2008-14	-1.0							-0.5	-1.0
Black	1975-94	5.5*	1994-14	-0.5									-0.5	-0.5
<u>SEER 13 Observed Incidence^b, 1992-2014</u>														
All Races	1992-10	0.2*	2010-14	-1.3									-0.5	-1.3
White	1992-95	2.7	1995-98	-2.2	1998-07	0.9*	2007-14	-0.9*					-0.5	-0.9*
White NH ^{ef}	1992-95	2.9	1995-98	-2.1	1998-07	1.0*	2007-14	-0.9*					-0.5	-0.9*
Black	1992-14	-0.3											-0.3	-0.3
Black NH ^{ef}	1992-14	-0.2											-0.2	-0.2
API ^e	1992-14	0.3*											0.3*	0.3*
AI/AN ^{eg}	1992-14	0.2											0.2	0.2
Hispanic ^f	1992-14	0.1											0.1	0.1
<u>U.S. Cancer Mortality^c, 1975-2014</u>														
All Races	1975-91	2.7*	1991-97	1.6*	1997-06	-2.9*	2006-14	-2.0*					-2.1*	-2.0*
White	1975-91	2.6*	1991-97	1.6*	1997-06	-2.8*	2006-14	-2.0*					-2.1*	-2.0*
Black	1975-96	2.7*	1996-14	-2.4*									-2.4*	-2.4*
<u>U.S. Cancer Mortality^c, 1992-2014</u>														
All Races	1992-97	1.7*	1997-06	-2.9*	2006-14	-2.0*							-2.1*	-2.0*
White	1992-97	1.7*	1997-06	-2.8*	2006-14	-2.0*							-2.1*	-2.0*
White NH ^{ef}	1992-97	1.7*	1997-14	-2.5*									-2.5*	-2.5*
Black	1992-96	2.6	1996-14	-2.3*									-2.3*	-2.3*
Black NH ^{ef}	1992-96	2.9	1996-14	-2.2*									-2.2*	-2.2*
API ^e	1992-14	-2.0*											-2.0*	-2.0*
AI/AN ^{eg}	1992-14	-0.5											-0.5	-0.5
Hispanic ^f	1992-96	4.5	1996-03	-3.9*	2003-14	-0.9*							-0.9*	-0.9*

Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute. (<https://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero ($p < .05$).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.3
Non-Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2014 With up to Five Joinpoints, 1992-2014 With up to Four Joinpoints,
Females by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2005-14	2010-14
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2014</u>														
All Races	1975-88	3.0*	1988-04	1.4*	2004-14	-0.6*							-0.6*	-0.6*
White	1975-88	3.1*	1988-04	1.4*	2004-14	-0.6*							-0.6*	-0.6*
Black	1975-04	2.9*	2004-14	-0.7									-0.7	-0.7
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2014</u>														
All Races	1992-04	1.3*	2004-14	-0.5*									-0.5*	-0.5*
White	1992-04	1.4*	2004-14	-0.5									-0.5	-0.5
Black	1992-98	5.6*	1998-14	0.5									0.5	0.5
<u>SEER 9 Observed Incidence^a, 1975-2014</u>														
All Races	1975-88	3.0*	1988-04	1.4*	2004-14	-0.9*							-0.9*	-0.9*
White	1975-88	3.0*	1988-04	1.4*	2004-14	-0.9*							-0.9*	-0.9*
Black	1975-04	2.9*	2004-14	-1.0									-1.0	-1.0
<u>SEER 13 Observed Incidence^b, 1992-2014</u>														
All Races	1992-04	1.4*	2004-14	-0.8*									-0.8*	-0.8*
White	1992-04	1.4*	2004-14	-0.8*									-0.8*	-0.8*
White NH ^{ef}	1992-04	1.5*	2004-14	-0.9*									-0.9*	-0.9*
Black	1992-98	5.8*	1998-14	0.2									0.2	0.2
Black NH ^{ef}	1992-03	3.1*	2003-14	-0.4									-0.4	-0.4
API ^e	1992-14	0.2											0.2	0.2
AI/AN ^{eg}	1992-14	2.1*											2.1*	2.1*
Hispanic ^f	1992-14	0.8*											0.8*	0.8*
<u>U.S. Cancer Mortality^c, 1975-2014</u>														
All Races	1975-94	2.2*	1994-97	1.0	1997-09	-3.2*	2009-14	-2.2*					-2.7*	-2.2*
White	1975-97	2.1*	1997-04	-3.8*	2004-14	-2.7*							-2.7*	-2.7*
Black	1975-96	2.7*	1996-14	-2.2*									-2.2*	-2.2*
<u>U.S. Cancer Mortality^c, 1992-2014</u>														
All Races	1992-94	2.9*	1994-97	1.0	1997-09	-3.2*	2009-14	-2.2*					-2.7*	-2.2*
White	1992-94	3.3*	1994-97	0.6	1997-00	-2.5	2000-03	-4.4*	2003-14	-2.7*			-2.7*	-2.7*
White NH ^{ef}	1992-94	3.9*	1994-97	0.9	1997-11	-3.2*	2011-14	-1.6					-2.7*	-2.0*
Black	1992-97	1.7	1997-14	-2.2*									-2.2*	-2.2*
Black NH ^{ef}	1992-97	1.9	1997-14	-2.2*									-2.2*	-2.2*
API ^e	1992-14	-1.7*											-1.7*	-1.7*
AI/AN ^{eg}	1992-01	5.6*	2001-14	-4.5*									-4.5*	-4.5*
Hispanic ^f	1992-97	3.0	1997-14	-2.1*									-2.1*	-2.1*

Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute. (<https://surveillance.cancer.gov/joinpoint/>).
^a The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
^b Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
^c Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).
^d Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
^e The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.
^f API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic
Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.
^g Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
* The APC/AAPC is significantly different from zero (p<.05).
- Joinpoint regression line analysis could not be performed on data series.

Table 19.4
Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	11.06	12.89	9.57	11.61	13.49	10.10	6.36	7.31	5.31
1976	11.21	12.82	10.06	11.65	13.27	10.51	6.04	7.45	5.03
1977	11.18	12.92	9.82	11.64	13.51	10.20	6.64	7.23	6.10
1978	11.92	14.26	10.12	12.47	14.74	10.74	7.15	9.46	5.17
1979	12.53	14.22	11.21	13.00	14.60	11.77	8.46	11.95	5.91
1980	12.62	15.01	10.81	12.97	15.26	11.22	8.77	10.89	7.20
1981	13.58	15.90	11.81	14.06	16.34	12.35	7.42	10.59	4.98
1982	13.39	15.56	11.61	14.02	16.42	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.63	17.52	12.40	10.28	10.88	9.62
1984	15.19	18.29	12.79	15.97	19.10	13.55	9.46	12.52	6.92
1985	15.51	18.39	13.16	16.28	19.24	13.85	9.95	11.96	8.43
1986	15.90	19.43	13.00	16.82	20.57	13.75	10.66	13.13	8.52
1987	16.74	20.79	13.42	17.70	22.15	14.00	10.35	10.43	9.95
1988	17.25	21.33	14.08	18.21	22.42	14.90	11.58	15.79	8.49
1989	17.35	21.64	13.84	18.35	23.02	14.50	11.59	14.10	9.72
1990	18.50	22.97	14.81	19.33	23.93	15.50	13.92	17.63	11.02
1991	18.81	23.73	14.61	19.69	24.81	15.31	14.03	18.72	10.37
1992	18.62	23.04	14.94	19.55	23.94	15.83	13.68	18.87	9.65
1993	18.86	23.47	15.01	19.65	24.29	15.72	14.11	19.37	9.78
1994	19.95	24.96	15.79	20.67	25.58	16.55	14.43	21.52	8.77
1995	19.98	25.41	15.43	20.68	26.16	16.02	16.70	23.54	11.38
1996	19.42	24.23	15.48	20.26	25.19	16.19	15.46	19.19	12.30
1997	19.99	24.52	16.45	20.88	25.21	17.47	16.34	24.16	10.84
1998	19.61	22.95	16.85	20.58	23.98	17.75	14.49	16.96	12.54
1999	19.96	24.60	16.33	20.91	25.48	17.29	14.38	18.42	11.31
2000	19.79	24.33	16.12	20.94	25.66	17.07	13.89	18.23	10.66
2001	20.01	24.40	16.45	20.80	25.44	17.03	16.05	18.44	13.92
2002	20.22	24.20	17.08	21.31	25.49	17.96	14.45	17.10	12.45
2003	20.77	25.05	17.51	21.90	26.32	18.46	16.11	19.72	13.59
2004	21.39	25.88	17.95	22.33	26.81	18.84	18.48	24.03	14.47
2005	20.87	25.63	17.07	22.01	26.75	18.17	16.79	20.10	14.10
2006	20.55	24.79	17.27	21.80	26.11	18.41	16.42	21.04	12.98
2007	21.33	26.20	17.44	22.62	27.62	18.52	15.87	19.40	13.20
2008	21.03	25.88	17.08	21.91	26.94	17.73	17.04	19.14	15.15
2009	21.03	25.35	17.53	22.12	26.81	18.20	15.44	18.75	13.01
2010	21.55	26.81	17.27	22.49	27.59	18.29	17.94	23.43	13.57
2011	20.04	24.56	16.46	21.01	25.71	17.26	14.74	17.65	12.58
2012	20.53	25.12	16.80	21.49	26.20	17.60	16.92	19.29	14.82
2013	20.02	24.49	16.38	21.13	25.72	17.31	15.91	18.33	14.07
2014	20.62	25.51	16.64	21.90	26.80	17.88	15.25	19.95	11.62

Additional information on the model used to delay-adjust SEER Incidence rates can be found at [\(https://surveillance.cancer.gov/delay/\)](https://surveillance.cancer.gov/delay/).

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval.

Table 19.5
Non-Hodgkin Lymphoma

Age-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2014	18.35	22.52	15.05	19.12	23.39	15.71	13.95	17.45	11.20
1975	11.06	12.89	9.57	11.61	13.49	10.10	6.36	7.31	5.31
1976	11.21	12.82	10.06	11.65	13.27	10.51	6.04	7.45	5.03
1977	11.18	12.92	9.82	11.64	13.51	10.20	6.64	7.23	6.10
1978	11.92	14.26	10.12	12.47	14.74	10.74	7.15	9.46	5.17
1979	12.53	14.22	11.21	13.00	14.60	11.77	8.46	11.95	5.91
1980	12.62	15.01	10.81	12.97	15.26	11.22	8.77	10.89	7.20
1981	13.58	15.90	11.81	14.06	16.34	12.35	7.42	10.59	4.98
1982	13.39	15.56	11.61	14.02	16.42	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.63	17.52	12.40	10.28	10.88	9.62
1984	15.19	18.29	12.79	15.97	19.10	13.55	9.46	12.52	6.92
1985	15.51	18.39	13.16	16.28	19.24	13.85	9.95	11.96	8.43
1986	15.90	19.43	13.00	16.82	20.57	13.75	10.66	13.13	8.52
1987	16.74	20.79	13.42	17.70	22.15	14.00	10.35	10.43	9.95
1988	17.25	21.33	14.08	18.21	22.42	14.90	11.58	15.79	8.49
1989	17.35	21.64	13.84	18.35	23.02	14.50	11.59	14.10	9.72
1990	18.50	22.97	14.81	19.33	23.93	15.50	13.92	17.63	11.02
1991	18.81	23.73	14.61	19.69	24.81	15.31	14.03	18.72	10.37
1992	18.62	23.04	14.94	19.55	23.94	15.83	13.68	18.87	9.65
1993	18.86	23.47	15.01	19.65	24.29	15.72	14.11	19.37	9.78
1994	19.95	24.96	15.79	20.67	25.58	16.55	14.43	21.52	8.77
1995	19.98	25.41	15.43	20.68	26.16	16.02	16.70	23.54	11.38
1996	19.42	24.23	15.48	20.26	25.19	16.19	15.46	19.19	12.30
1997	19.99	24.52	16.45	20.88	25.21	17.47	16.34	24.16	10.84
1998	19.61	22.95	16.85	20.58	23.98	17.75	14.49	16.96	12.54
1999	19.96	24.60	16.33	20.91	25.48	17.29	14.38	18.42	11.31
2000	19.79	24.33	16.12	20.94	25.66	17.07	13.89	18.23	10.66
2001	20.01	24.40	16.45	20.80	25.44	17.03	16.05	18.44	13.92
2002	20.22	24.20	17.08	21.31	25.49	17.96	14.45	17.10	12.45
2003	20.77	25.05	17.51	21.90	26.32	18.46	16.11	19.72	13.59
2004	21.39	25.88	17.95	22.33	26.81	18.84	18.48	24.03	14.47
2005	20.87	25.63	17.07	22.01	26.75	18.17	16.79	20.10	14.10
2006	20.51	24.74	17.24	21.76	26.06	18.37	16.37	20.97	12.94
2007	21.24	26.10	17.38	22.53	27.51	18.44	15.77	19.29	13.12
2008	20.91	25.72	16.98	21.77	26.77	17.62	16.87	18.94	14.99
2009	20.86	25.16	17.39	21.93	26.58	18.04	15.23	18.50	12.82
2010	21.34	26.55	17.10	22.25	27.30	18.09	17.67	23.06	13.38
2011	19.80	24.28	16.26	20.74	25.38	17.03	14.45	17.30	12.34
2012	20.22	24.75	16.54	21.12	25.75	17.29	16.52	18.82	14.47
2013	19.63	24.01	16.05	20.66	25.15	16.92	15.42	17.77	13.63
2014	19.96	24.70	16.11	21.09	25.81	17.22	14.57	19.06	11.10

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.6
Non-Hodgkin Lymphoma

Age-adjusted U.S. Death^a Rates by Year, Race and Sex

Year of Death:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2014	7.13	8.93	5.80	7.43	9.28	6.06	4.85	6.22	3.85
1975	5.63	6.92	4.65	5.83	7.15	4.82	3.74	4.83	2.92
1976	5.71	6.87	4.83	5.94	7.14	5.03	3.54	4.54	2.76
1977	5.77	6.88	4.92	5.96	7.10	5.10	3.89	4.89	3.12
1978	5.93	7.30	4.90	6.15	7.53	5.12	3.90	5.40	2.81
1979	5.95	7.40	4.88	6.18	7.70	5.08	3.65	4.50	2.98
1980	6.23	7.47	5.29	6.47	7.74	5.52	3.99	5.15	3.12
1981	6.16	7.38	5.27	6.40	7.66	5.47	3.98	5.00	3.25
1982	6.55	7.98	5.49	6.83	8.29	5.74	4.12	5.23	3.29
1983	6.66	8.11	5.58	6.92	8.39	5.85	4.30	5.79	3.23
1984	6.76	8.15	5.75	7.05	8.50	6.01	4.19	5.28	3.39
1985	7.06	8.80	5.80	7.34	9.17	6.02	4.62	5.57	3.87
1986	7.31	8.98	6.05	7.59	9.25	6.33	4.95	6.64	3.70
1987	7.26	8.81	6.10	7.56	9.12	6.38	4.73	6.30	3.62
1988	7.52	9.28	6.24	7.82	9.59	6.53	5.01	6.82	3.72
1989	7.83	9.73	6.43	8.12	10.04	6.71	5.33	7.10	4.07
1990	7.87	9.97	6.34	8.16	10.32	6.58	5.39	7.13	4.17
1991	8.19	10.15	6.74	8.50	10.52	7.00	5.70	7.17	4.61
1992	8.22	10.30	6.69	8.53	10.66	6.96	5.64	7.23	4.45
1993	8.25	10.14	6.86	8.57	10.45	7.17	5.69	7.53	4.40
1994	8.63	10.75	7.10	9.00	11.20	7.41	5.54	6.82	4.56
1995	8.72	10.81	7.16	9.09	11.21	7.49	5.79	7.62	4.45
1996	8.75	10.94	7.14	9.09	11.29	7.46	6.21	8.25	4.74
1997	8.88	11.03	7.25	9.21	11.35	7.57	6.34	8.45	4.87
1998	8.69	10.85	7.10	9.03	11.27	7.38	5.99	7.50	4.89
1999	8.32	10.36	6.85	8.67	10.71	7.18	5.65	7.44	4.41
2000	8.17	10.20	6.70	8.54	10.63	7.01	5.20	6.61	4.17
2001	7.91	9.98	6.42	8.21	10.31	6.68	5.61	7.28	4.47
2002	7.65	9.66	6.19	7.97	10.04	6.44	5.41	6.88	4.41
2003	7.38	9.40	5.92	7.69	9.81	6.13	4.94	5.83	4.27
2004	7.09	8.94	5.73	7.38	9.28	5.96	5.01	6.23	4.13
2005	6.95	8.87	5.56	7.24	9.22	5.79	4.77	6.11	3.81
2006	6.74	8.48	5.44	7.01	8.78	5.66	4.92	6.27	3.93
2007	6.59	8.36	5.26	6.86	8.67	5.49	4.52	5.77	3.62
2008	6.41	8.20	5.09	6.71	8.56	5.33	4.31	5.48	3.45
2009	6.30	8.12	4.93	6.56	8.42	5.13	4.49	6.15	3.41
2010	6.14	7.83	4.85	6.37	8.11	5.04	4.57	5.84	3.64
2011	6.03	7.85	4.64	6.29	8.17	4.83	4.36	5.74	3.39
2012	5.91	7.62	4.61	6.17	7.95	4.80	4.26	5.38	3.48
2013	5.70	7.38	4.44	5.95	7.67	4.62	4.11	5.27	3.33
2014	5.66	7.27	4.43	5.90	7.56	4.61	4.19	5.29	3.42

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.7
Non-Hodgkin Lymphoma

SEER Incidence^a and U.S. Death^b Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2010-2014									
All ages	19.5	23.7	16.0	20.4	24.8	16.9	14.6	17.6	12.2
Under 65	9.1	10.8	7.5	9.4	11.0	7.7	8.9	10.8	7.2
65 and over	90.8	113.0	74.7	96.7	119.8	79.8	53.7	64.7	46.8
All ages (WHO world std) ^c	14.5	17.5	12.0	15.2	18.2	12.5	11.5	14.0	9.6
Age-Specific Rates, 2010-2014									
<1	-	-	-	-	-	-	-	-	-
1-4	0.7	0.9	0.5	0.7	0.9	0.5	0.7	-	-
5-9	1.2	1.6	0.7	1.2	1.7	0.6	1.1	1.4	0.8
10-14	1.4	1.8	1.0	1.4	1.7	1.1	1.5	1.9	1.0
15-19	1.9	2.5	1.2	1.8	2.4	1.3	1.7	2.4	0.9
20-24	2.6	3.1	2.1	2.6	3.0	2.1	2.7	3.6	1.7
25-29	3.3	3.8	2.8	3.2	3.7	2.7	3.9	4.4	3.4
30-34	4.7	5.5	3.9	4.5	5.2	3.8	6.0	7.1	4.9
35-39	6.9	8.0	5.8	6.8	7.9	5.7	8.5	10.3	6.9
40-44	9.7	11.5	8.0	9.8	11.4	8.1	10.7	13.0	8.6
45-49	14.3	16.9	11.7	14.7	17.1	12.2	15.2	19.3	11.5
50-54	21.5	25.2	17.9	22.2	26.1	18.4	20.8	24.2	17.8
55-59	30.4	35.2	25.8	31.6	36.4	27.0	26.7	33.0	21.3
60-64	43.8	52.3	36.1	46.3	55.1	38.0	33.9	40.7	28.4
65-69	63.6	75.2	53.3	67.2	78.6	56.8	46.2	53.6	40.5
70-74	82.5	99.9	68.0	88.4	106.1	73.3	49.4	60.7	41.3
75-79	105.0	127.7	87.4	112.5	136.2	93.6	62.7	71.4	57.0
80-84	119.7	152.0	97.6	128.5	162.6	104.6	62.7	78.3	54.1
85+	109.7	152.8	87.5	115.1	161.1	91.3	53.1	70.3	45.9
<u>U.S. Mortality</u>									
<u>Age at Death</u>									
Age-Adjusted Rates, 2010-2014									
All ages	5.9	7.6	4.6	6.1	7.9	4.8	4.3	5.5	3.5
Under 65	1.4	1.9	1.0	1.4	1.9	1.0	1.7	2.2	1.3
65 and over	36.6	47.0	29.3	38.6	49.4	30.8	22.1	28.1	18.4
All ages (WHO world std) ^c	3.8	4.9	2.9	3.9	5.1	3.0	3.0	3.9	2.4
Age-Specific Rates, 2010-2014									
<1	-	-	-	-	-	-	-	-	-
1-4	0.0	0.0	-	-	-	-	-	-	-
5-9	0.1	0.1	0.0	0.1	0.1	-	-	-	-
10-14	0.1	0.1	0.1	0.1	0.1	0.1	0.1	-	-
15-19	0.1	0.2	0.1	0.1	0.2	0.1	0.1	-	-
20-24	0.3	0.3	0.2	0.3	0.3	0.2	0.3	0.4	0.3
25-29	0.4	0.5	0.3	0.4	0.5	0.3	0.7	0.9	0.5
30-34	0.5	0.7	0.4	0.5	0.6	0.4	0.9	1.2	0.5
35-39	0.8	1.0	0.5	0.7	0.9	0.5	1.3	1.7	1.0
40-44	1.2	1.5	0.9	1.1	1.5	0.8	1.9	2.1	1.7
45-49	1.9	2.5	1.4	1.9	2.4	1.3	2.7	3.4	2.0
50-54	3.3	4.4	2.3	3.3	4.4	2.3	4.1	5.6	2.8
55-59	5.7	7.5	3.9	5.8	7.7	4.0	5.7	7.3	4.3
60-64	9.6	12.5	6.8	9.8	12.9	6.9	9.3	12.3	6.9
65-69	15.4	19.5	11.7	16.1	20.4	12.1	12.6	15.2	10.5
70-74	25.5	32.2	19.8	26.9	33.8	20.9	17.9	23.5	13.8
75-79	39.0	49.4	30.9	41.3	52.0	32.7	23.6	29.4	19.9
80-84	58.5	75.4	46.9	61.8	79.3	49.5	32.6	44.0	26.4
85+	76.5	101.3	64.1	80.9	106.7	67.8	37.0	45.7	33.5

^a SEER 18 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

- Rates are per 100,000 and are age-adjusted to the world (WHO 2000-2025) standard million.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.5	45.6	47.5	46.8	46.3	47.3	48.6	42.6	55.3 ^g
1978-1980 ^b	47.9	46.1	49.8	47.9	46.2	49.5	51.3	47.3	56.7
1981-1983 ^b	50.6	50.3	50.9	50.8	50.5	51.1	49.5	49.2	49.8
1984-1986 ^b	51.6	50.1	53.3	52.0	50.6	53.6	46.8	44.5	49.9
1987-1989 ^b	50.9	47.6	54.9	51.3	48.1	55.2	45.7	41.3	51.0
1990-1992 ^b	50.7	46.7	55.7	51.5	47.6	56.4	42.2	38.2	47.7
1993-1995 ^b	52.5	48.7	57.5	53.2	49.7	57.7	42.1	35.7	54.0
1996-1998 ^b	58.8	57.0	61.0	59.4	57.6	61.5	54.6	53.0	57.0
1999-2001 ^b	63.9	61.4	66.9	64.9	62.8	67.5	55.7	49.0	63.7
2002-2006 ^b	70.3	68.9	71.9	71.6	70.7	72.8	62.4	58.1	67.6
2007-2013 ^b	73.3 ^f	72.5 ^f	74.3 ^f	74.2 ^f	73.5 ^f	75.1 ^f	67.1 ^f	63.5 ^f	71.0 ^f
5-Year Period Survival (Percent) ^{cd}									
2013	71.4	69.8	73.3	71.8	70.4	73.5	65.9	61.6	70.8
Stage Distribution (%) 2007-2013 ^{ce}									
All Stages									
Number of cases	95,444	51,995	43,449	78,911	43,105	35,806	7,881	4,194	3,687
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	26	29	27	26	29	28	25	31
Regional	15	15	15	15	15	15	15	14	15
Distant	50	51	48	50	52	49	51	55	47
Unstaged	8	7	8	7	7	8	6	6	7
5-Year Relative Survival (Percent), 2007-2013 ^c									
Age at Diagnosis:									
Ages <45	82.5	80.1	86.1	84.1	81.7	87.8	71.3	68.2	75.9
Ages 45-54	79.9	76.6	84.8	81.6	78.6	86.1	66.6	61.4	74.1
Ages 55-64	76.3	73.7	79.7	77.4	75.0	80.6	65.1	59.7	71.9
Ages 65-74	70.7	68.3	73.3	71.2	68.8	74.0	64.6	58.6	69.3
Ages 75+	55.0	52.8	56.8	55.4	52.8	57.5	50.2	44.7	52.5
Ages <65	79.0	76.3	82.8	80.3	77.8	83.9	67.9	63.4	74.0
Ages 65+	62.4	60.8	63.9	62.7	60.9	64.5	58.4	53.5	61.5
Stage ^e :									
All Stages	71.0	69.5	72.7	71.4	70.0	73.0	65.1	61.3	69.4
Localized	82.9	82.3	83.5	83.0	82.6	83.5	80.0	75.6	83.9
Regional	75.0	74.5	75.4	75.5	75.1	75.9	70.4	69.5	71.0
Distant	63.4	61.9	65.4	64.4	62.8	66.4	55.9	53.0	59.7
Unstaged	69.2	66.6	72.0	67.7	65.0	70.6	61.9	57.6	66.0

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2014.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2014.

^d Period survival provides a 2013 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2007-2013 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 19.9
Non-Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Survival Time																							
1-year	70.2	73.0	71.3	70.4	70.3	73.2	75.6	76.7	77.4	77.3	78.7	81.0	80.3	81.1	81.7	81.0	81.6	84.1	83.9	84.3	83.4	84.1	84.3
2-year	60.2	63.7	62.8	62.2	61.7	65.9	68.5	70.0	71.0	71.4	73.3	76.0	75.7	76.0	77.3	76.9	77.5	79.0	79.5	79.5	79.7	79.8	
3-year	54.6	58.5	58.2	57.7	57.5	62.0	64.8	66.4	66.9	67.9	70.0	73.1	73.1	73.5	74.8	74.5	75.0	76.1	77.2	77.3	77.4		
4-year	50.5	54.6	54.3	54.4	54.7	58.6	62.1	63.6	64.4	65.4	68.0	71.2	71.6	71.5	72.9	72.6	73.1	74.3	75.5	75.1			
5-year	46.8	50.7	51.0	51.6	51.9	56.0	59.4	60.9	62.0	63.8	65.9	69.2	70.0	70.1	71.6	70.5	71.2	72.7	74.0				
6-year	43.6	47.5	48.3	49.2	49.8	54.1	57.1	58.3	59.5	62.0	64.6	68.0	68.3	68.7	70.3	68.8	70.0	71.7					
7-year	40.8	45.0	45.8	46.9	47.8	52.1	55.1	56.4	57.7	60.4	62.8	66.2	67.1	67.2	68.4	67.2	68.6						
8-year	38.5	42.8	43.4	45.0	46.3	50.4	52.8	55.2	56.2	58.8	61.2	65.1	65.7	66.5	66.9	66.0							
9-year	36.6	40.8	41.5	43.4	45.2	49.3	51.5	53.4	54.8	57.5	59.9	64.0	64.8	64.9	65.0								
10-year	35.0	38.9	39.8	42.1	44.2	48.1	50.0	52.1	53.6	56.2	58.8	63.1	63.3	63.7									
11-year	33.5	37.4	38.5	40.6	43.3	46.6	48.7	51.0	52.5	54.7	58.0	61.7	62.1										
12-year	32.4	36.0	36.9	39.5	42.2	45.6	48.0	50.1	51.1	53.4	56.7	59.9											
13-year	31.4	34.8	35.7	38.3	41.3	44.8	46.8	49.1	49.9	51.9	56.0												
14-year	30.2	33.5	34.7	37.1	40.5	44.3	45.5	48.4	48.7	51.1													
15-year	28.9	32.2	33.5	36.4	39.7	43.7	44.5	47.3	47.7														
16-year	27.9	31.2	32.8	35.6	39.1	43.6	43.1	47.1															
17-year	27.4	30.4	32.1	34.8	38.6	42.7	42.6																
18-year	26.7	29.6	31.3	34.0	37.6	41.8																	
19-year	26.0	28.8	30.6	33.2	36.8																		
20-year	25.2	28.0	30.1	32.8																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.10
Non-Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Survival Time																							
1-year	69.4	72.7	68.9	67.1	66.6	71.2	74.7	74.9	75.8	76.5	77.6	80.6	79.7	80.1	81.1	81.0	81.4	83.6	82.7	83.7	83.7	84.0	83.4
2-year	59.4	63.7	60.5	58.2	58.3	63.6	67.1	68.2	69.1	70.3	71.3	75.2	74.9	75.4	76.2	76.5	77.8	77.9	78.1	78.7	79.7	79.0	
3-year	53.4	58.0	55.7	53.7	54.5	59.8	63.8	64.5	64.4	66.8	67.9	72.0	72.6	72.6	73.1	73.6	75.4	75.1	75.6	76.5	77.4		
4-year	49.3	53.9	51.6	50.4	51.5	56.1	61.0	62.0	61.5	63.9	65.7	70.0	70.8	70.1	71.1	71.3	73.3	73.3	73.6	74.2			
5-year	45.5	50.1	48.2	47.6	48.5	53.7	58.2	59.2	59.0	61.7	63.5	67.9	68.9	68.8	69.9	68.9	71.0	72.1	72.2				
6-year	42.6	46.6	45.5	45.6	46.8	51.0	56.1	56.5	56.2	60.2	62.0	66.7	66.9	67.5	68.4	67.0	69.6	71.4					
7-year	39.9	44.2	43.1	43.6	44.8	49.1	54.2	54.4	54.6	58.6	60.1	65.3	65.7	65.4	66.7	65.0	68.1						
8-year	37.8	42.0	41.0	41.8	43.2	47.4	52.0	53.3	53.6	56.6	58.2	63.7	64.4	64.8	64.9	63.3							
9-year	35.7	40.1	39.1	40.2	42.3	46.4	50.4	51.4	52.3	55.2	57.2	62.8	63.2	63.0	63.4								
10-year	34.0	38.0	37.7	39.1	41.5	45.5	48.8	50.3	51.5	54.2	55.9	61.7	61.6	61.9									
11-year	32.8	36.3	36.4	38.0	40.7	43.7	47.6	49.3	50.7	52.7	54.6	60.3	60.4										
12-year	31.9	35.2	35.1	37.2	39.4	42.7	47.0	48.1	49.8	51.4	53.6	58.9											
13-year	30.7	34.2	34.2	36.1	38.8	41.9	45.4	46.7	49.0	50.1	53.0												
14-year	29.5	33.1	33.2	34.9	37.7	41.4	44.2	46.1	48.0	49.5													
15-year	28.1	31.9	32.3	34.3	36.7	40.9	43.3	45.2	47.2														
16-year	27.2	30.8	31.6	33.3	36.0	40.9	42.3	45.2															
17-year	26.5	30.0	30.8	32.5	35.6	40.3	41.7																
18-year	26.1	29.4	30.2	31.9	34.9	39.5																	
19-year	25.6	28.8	29.3	31.2	34.1																		
20-year	25.0	28.0	29.1	30.9																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.11
Non-Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Survival Time																							
1-year	71.0	73.4	74.0	74.7	75.2	75.8	76.7	78.6	79.2	78.2	80.0	81.4	81.0	82.2	82.5	80.9	81.9	84.6	85.3	85.1	83.0	84.2	85.3
2-year	61.1	63.7	65.6	67.2	66.3	68.7	70.1	72.0	73.3	72.7	75.7	76.9	76.5	76.8	78.5	77.4	77.1	80.3	81.2	80.6	79.7	80.7	
3-year	55.9	58.9	61.1	62.8	61.5	64.9	66.1	68.4	69.9	69.2	72.6	74.3	73.6	74.6	76.8	75.6	74.5	77.3	79.1	78.5	77.4		
4-year	51.9	55.3	57.6	59.5	58.9	61.8	63.4	65.3	68.0	67.4	70.9	72.4	72.4	73.1	75.1	74.0	72.8	75.5	77.7	76.2			
5-year	48.2	51.4	54.3	56.7	56.4	59.0	60.7	62.9	65.7	66.4	68.8	70.7	71.3	71.7	73.5	72.5	71.3	73.4	76.1				
6-year	44.6	48.4	51.7	53.9	53.9	58.0	58.3	60.3	63.3	64.2	67.8	69.5	69.9	70.2	72.6	70.9	70.5	72.0					
7-year	41.7	45.8	49.0	51.2	51.8	56.0	56.3	58.5	61.4	62.6	66.2	67.3	68.7	69.3	70.3	69.7	69.2						
8-year	39.2	43.7	46.3	49.1	50.4	54.1	53.9	57.3	59.5	61.5	64.8	66.7	67.2	68.5	69.2	69.1							
9-year	37.4	41.6	44.3	47.5	49.1	52.9	52.8	55.7	57.7	60.2	63.1	65.3	66.4	66.9	66.9								
10-year	36.0	39.9	42.4	45.8	47.8	51.3	51.5	54.2	56.0	58.7	62.3	64.7	65.1	65.8									
11-year	34.2	38.5	40.9	43.8	46.7	50.2	49.9	52.8	54.5	57.1	61.9	63.4	64.0										
12-year	32.9	36.8	39.1	42.5	45.8	49.3	49.2	52.2	52.7	55.9	60.4	61.1											
13-year	32.1	35.3	37.6	41.1	44.8	48.5	48.4	51.6	50.9	54.1	59.6												
14-year	31.0	34.0	36.5	39.9	44.1	47.8	46.9	51.1	49.5	52.9													
15-year	29.7	32.6	34.9	39.1	43.5	47.1	45.9	49.6	48.1														
16-year	28.7	31.6	34.2	38.5	43.3	46.5	43.9	49.0															
17-year	28.2	30.6	33.6	37.7	42.6	45.7	43.6																
18-year	27.4	29.8	32.7	36.7	41.1	44.7																	
19-year	26.4	28.8	32.1	35.7	40.4																		
20-year	25.4	28.0	31.2	35.2																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.12

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	5,222	2,506	2,704	3,176	3,627	3,990	4,568	4,729	5,324	5,257	5,262	5,560	5,775	6,224	6,396	6,694	6,979	10,696
SEER 9 except SF-Oakland	4,285	2,088	2,267	2,603	2,819	3,088	3,505	3,694	4,158	4,247	4,364	4,513	4,818	5,206	5,395	5,621	5,828	9,043
San Francisco-Oakland SMSA ^c	937	418	437	573	808	902	1,063	1,035	1,166	1,010	898	1,047	957	1,018	1,001	1,073	1,151	1,653
San Francisco City/County	245	96	123	210	326	393	467	410	450	353	213	256	220	283	219	215	239	348

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	13.4	15.5	16.1	18.3	20.1	21.5	23.3	23.3	25.2	24.4	23.8	24.4	24.6	25.8	25.4	25.4	25.4	24.5
SEER 9 except SF-Oakland	13.2	15.4	16.1	18.1	18.8	20.0	21.6	21.8	23.6	23.5	23.5	23.6	24.4	25.6	25.4	25.3	25.2	24.5
San Francisco-Oakland SMSA ^c	14.7	15.8	16.0	19.4	26.7	28.4	31.7	30.5	33.5	28.8	25.1	28.6	25.6	26.6	25.6	26.2	26.7	24.2
San Francisco City/County	14.3	14.4	17.6	29.3	44.4	51.9	61.0	52.3	57.4	44.6	27.4	32.5	26.9	35.4	26.5	25.5	27.2	25.5

^a Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.13

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, Ages 0-19

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	223	87	108	91	94	84	100	89	120	105	104	119	127	106	106	142	133	233
SEER 9 except SF-Oakland	191	78	95	82	80	76	86	74	107	84	93	100	115	89	87	114	118	193
San Francisco-Oakland SMSA ^c	32	9	13	9	14	8	14	15	13	21	11	19	12	17	19	28	15	40
San Francisco City/County	9	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	5	<4	6

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, Ages 0-19

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	1.2	1.2	1.6	1.4	1.4	1.3	1.5	1.3	1.7	1.4	1.4	1.5	1.6	1.4	1.3	1.8	1.7	2.0
SEER 9 except SF-Oakland	1.2	1.3	1.6	1.4	1.4	1.3	1.5	1.2	1.7	1.3	1.4	1.5	1.7	1.3	1.3	1.6	1.7	1.9
San Francisco-Oakland SMSA ^c	1.4	1.0	1.5	1.0	1.6	0.9	1.5	1.6	1.3	2.1	1.1	1.8	1.2	1.7	1.9	2.7	1.4	2.6
San Francisco City/County	2.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.0	-	3.2

^a Rates are per 100,000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.14

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, Ages 20-54

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	1,463	687	723	958	1,211	1,411	1,764	1,830	2,089	1,767	1,606	1,695	1,624	1,721	1,653	1,695	1,669	2,335
SEER 9 except SF-Oakland	1,208	563	588	730	827	922	1,193	1,294	1,483	1,323	1,269	1,326	1,309	1,408	1,380	1,403	1,398	1,942
San Francisco-Oakland SMSA ^c	255	124	135	228	384	489	571	536	606	444	337	369	315	313	273	292	271	393
San Francisco City/County	58	29	34	105	215	288	333	303	317	224	105	115	111	111	86	75	72	106

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, Ages 20-54

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	6.9	7.9	8.2	10.4	12.4	13.5	15.9	15.6	16.9	13.8	12.1	12.3	11.7	12.3	11.6	11.9	11.5	10.8
SEER 9 except SF-Oakland	6.9	7.8	8.1	9.7	10.3	10.9	13.1	13.4	14.4	12.3	11.5	11.6	11.2	11.9	11.5	11.6	11.5	10.7
San Francisco-Oakland SMSA ^c	6.9	8.4	8.9	13.9	22.6	26.4	29.5	26.7	29.8	21.2	15.5	16.4	13.9	14.1	12.3	13.0	11.7	11.1
San Francisco City/County	6.7	8.8	9.4	27.2	56.5	71.5	81.3	72.4	74.4	50.7	23.0	25.2	23.9	24.8	19.4	16.2	15.0	14.5

^a Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.15

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	3,536	1,732	1,873	2,127	2,322	2,495	2,704	2,810	3,115	3,385	3,552	3,746	4,024	4,397	4,637	4,857	5,177	8,128
SEER 9 except SF-Oakland	2,886	1,447	1,584	1,791	1,912	2,090	2,226	2,326	2,568	2,840	3,002	3,087	3,394	3,709	3,928	4,104	4,312	6,908
San Francisco-Oakland SMSA ^c	650	285	289	336	410	405	478	484	547	545	550	659	630	688	709	753	865	1,220
San Francisco City/County	178	65	88	104	109	105	132	106	130	126	106	141	108	169	131	135	164	236

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2014

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2014
SEER 9 ^b	45.1	52.2	54.0	59.6	63.3	67.2	70.1	70.6	76.1	80.0	81.1	83.1	85.8	90.0	90.1	88.9	89.7	86.7
SEER 9 except SF-Oakland	44.0	52.1	54.4	60.1	62.0	66.7	68.7	69.2	74.4	79.7	81.3	81.3	85.8	90.1	90.4	89.0	88.6	87.3
San Francisco-Oakland SMSA ^c	50.8	52.8	52.0	57.1	70.2	70.3	77.3	78.3	85.4	82.1	80.1	93.2	85.5	89.4	88.4	88.8	95.4	83.7
San Francisco City/County	48.2	44.6	59.8	72.7	73.9	75.7	93.4	74.7	91.4	87.2	72.7	93.4	69.0	104.7	76.4	76.3	89.0	81.0

^a Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.16
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Both Sexes, 2012-2014 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.03	0.06	2.11	0.75	Asian/ Pacific Islander	0	0.01	0.03	0.06	1.85	0.74
	10	0.02	0.05	0.10	2.12	0.75		10	0.02	0.05	0.09	1.85	0.74
	20	0.03	0.09	0.20	2.11	0.76		20	0.03	0.07	0.15	1.84	0.74
	30	0.06	0.17	0.41	2.10	0.76		30	0.04	0.13	0.28	1.82	0.74
	40	0.12	0.36	0.80	2.07	0.76		40	0.08	0.24	0.55	1.78	0.74
	50	0.25	0.70	1.36	2.00	0.77		50	0.16	0.47	0.99	1.72	0.74
	60	0.49	1.18	1.73	1.87	0.77		60	0.32	0.85	1.38	1.61	0.73
	70	0.79	1.41	-	1.56	0.74		70	0.57	1.13	-	1.38	0.69
80	0.83	-	-	1.04	0.63	80	0.67	-	-	0.96	0.57		
White	0	0.01	0.03	0.05	2.21	0.78	American Indian/ Alaska Native ^a	0	0.01	0.02	0.04	1.26	0.50
	10	0.02	0.05	0.10	2.22	0.79		10	0.02	0.03	0.06	1.26	0.51
	20	0.03	0.08	0.20	2.21	0.79		20	0.01	0.05	0.10	1.25	0.51
	30	0.06	0.17	0.42	2.20	0.80		30	0.03	0.09	0.21	1.26	0.52
	40	0.12	0.37	0.84	2.17	0.80		40	0.06	0.18	0.42	1.26	0.53
	50	0.26	0.74	1.44	2.11	0.81		50	0.13	0.38	0.71	1.25	0.54
	60	0.51	1.26	1.83	1.96	0.81		60	0.26	0.63	1.01	1.20	0.56
	70	0.84	1.50	-	1.64	0.78		70	0.41	0.85	-	1.07	0.57
80	0.88	-	-	1.08	0.66	80	0.59	-	-	0.89	0.54		
Black	0	0.01	0.02	0.06	1.31	0.44	Hispanic ^b	0	0.01	0.02	0.04	2.16	0.77
	10	0.02	0.05	0.12	1.33	0.45		10	0.01	0.04	0.09	2.17	0.77
	20	0.03	0.10	0.22	1.31	0.45		20	0.02	0.07	0.18	2.16	0.77
	30	0.07	0.19	0.41	1.30	0.45		30	0.05	0.15	0.38	2.16	0.78
	40	0.12	0.34	0.65	1.25	0.45		40	0.10	0.34	0.77	2.12	0.78
	50	0.23	0.55	0.90	1.17	0.45		50	0.24	0.67	1.32	2.06	0.77
	60	0.35	0.73	0.97	1.04	0.44		60	0.46	1.14	1.71	1.90	0.77
	70	0.45	0.74	-	0.82	0.41		70	0.75	1.38	-	1.59	0.73
80	0.42	-	-	0.53	0.34	80	0.79	-	-	1.06	0.59		

Devcan 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.17
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Males, 2012-2014 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.03	0.07	2.38	0.84	Asian/ Pacific Islander	0	0.01	0.04	0.07	2.13	0.85
	10	0.02	0.06	0.12	2.39	0.85		10	0.03	0.06	0.11	2.14	0.85
	20	0.03	0.10	0.23	2.38	0.85		20	0.03	0.08	0.18	2.12	0.85
	30	0.07	0.20	0.47	2.37	0.86		30	0.05	0.15	0.34	2.10	0.85
	40	0.14	0.41	0.93	2.35	0.87		40	0.10	0.29	0.68	2.06	0.86
	50	0.29	0.82	1.57	2.28	0.88		50	0.19	0.58	1.19	1.99	0.86
	60	0.57	1.38	2.01	2.15	0.89		60	0.41	1.04	1.65	1.87	0.85
	70	0.94	1.67	-	1.84	0.87		70	0.69	1.36	-	1.60	0.81
80	1.04	-	-	1.29	0.75	80	0.82	-	-	1.13	0.68		
White	0	0.01	0.03	0.07	2.48	0.88	American Indian/ Alaska Native ^a	0	0.01	0.04	0.06	1.33	0.62
	10	0.02	0.05	0.12	2.49	0.89		10	0.02	0.05	0.09	1.34	0.63
	20	0.03	0.09	0.23	2.48	0.89		20	0.02	0.07	0.13	1.32	0.64
	30	0.06	0.20	0.48	2.48	0.90		30	0.05	0.11	0.23	1.33	0.65
	40	0.14	0.42	0.97	2.46	0.91		40	0.07	0.19	0.45	1.32	0.67
	50	0.30	0.86	1.65	2.39	0.92		50	0.13	0.40	0.69	1.32	0.68
	60	0.60	1.46	2.12	2.26	0.93		60	0.30	0.61	0.97	1.30	0.72
	70	1.00	1.76	-	1.93	0.91		70	0.37	0.79	-	1.19	0.77
80	1.10	-	-	1.33	0.78	80	0.60	-	-	1.17	0.83		
Black	0	0.01	0.03	0.07	1.42	0.48	Hispanic ^b	0	0.01	0.03	0.05	2.34	0.87
	10	0.02	0.06	0.15	1.44	0.49		10	0.02	0.04	0.10	2.35	0.88
	20	0.04	0.12	0.26	1.43	0.49		20	0.02	0.08	0.19	2.34	0.89
	30	0.08	0.23	0.47	1.41	0.49		30	0.06	0.17	0.42	2.34	0.89
	40	0.15	0.40	0.75	1.36	0.49		40	0.12	0.37	0.83	2.31	0.89
	50	0.26	0.63	0.99	1.27	0.49		50	0.26	0.74	1.46	2.25	0.89
	60	0.41	0.82	1.07	1.13	0.48		60	0.50	1.27	1.91	2.11	0.89
	70	0.52	0.84	-	0.92	0.46		70	0.86	1.58	-	1.81	0.86
80	0.50	-	-	0.64	0.39	80	0.95	-	-	1.25	0.72		

Devcan 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.18
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Females, 2012-2014 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.02	0.04	1.87	0.66	Asian/ Pacific Islander	0	0.01	0.02	0.05	1.61	0.65
	10	0.01	0.04	0.08	1.88	0.67		10	0.02	0.04	0.08	1.62	0.66
	20	0.02	0.07	0.17	1.87	0.67		20	0.02	0.06	0.12	1.60	0.66
	30	0.05	0.14	0.35	1.86	0.67		30	0.04	0.10	0.23	1.58	0.66
	40	0.10	0.30	0.68	1.82	0.67		40	0.07	0.20	0.44	1.55	0.66
	50	0.21	0.59	1.17	1.76	0.67		50	0.13	0.38	0.82	1.50	0.65
	60	0.40	1.01	1.50	1.63	0.67		60	0.25	0.70	1.17	1.40	0.65
	70	0.67	1.21	-	1.35	0.65		70	0.47	0.96	-	1.21	0.61
80	0.69	-	-	0.87	0.55	80	0.57	-	-	0.85	0.50		
White	0	0.01	0.02	0.04	1.96	0.69	American Indian/ Alaska Native ^a	0	0.00	0.01	0.02	1.22	0.42
	10	0.01	0.04	0.08	1.97	0.70		10	0.01	0.02	0.03	1.23	0.42
	20	0.02	0.07	0.17	1.96	0.70		20	0.01	0.03	0.07	1.22	0.42
	30	0.05	0.14	0.35	1.95	0.70		30	0.02	0.06	0.19	1.23	0.43
	40	0.10	0.31	0.71	1.92	0.70		40	0.04	0.17	0.39	1.23	0.44
	50	0.22	0.63	1.24	1.85	0.71		50	0.13	0.35	0.74	1.23	0.45
	60	0.43	1.08	1.59	1.71	0.71		60	0.23	0.64	1.05	1.15	0.46
	70	0.71	1.28	-	1.41	0.68		70	0.45	0.90	-	1.02	0.46
80	0.73	-	-	0.90	0.57	80	0.59	-	-	0.74	0.38		
Black	0	0.01	0.02	0.04	1.21	0.41	Hispanic ^b	0	0.00	0.02	0.04	2.01	0.68
	10	0.01	0.03	0.09	1.23	0.42		10	0.01	0.03	0.08	2.03	0.69
	20	0.02	0.08	0.18	1.22	0.42		20	0.02	0.06	0.16	2.02	0.69
	30	0.06	0.16	0.34	1.20	0.42		30	0.04	0.14	0.34	2.00	0.69
	40	0.10	0.29	0.57	1.16	0.42		40	0.09	0.30	0.70	1.97	0.68
	50	0.19	0.48	0.81	1.09	0.41		50	0.21	0.62	1.21	1.90	0.68
	60	0.31	0.66	0.89	0.96	0.41		60	0.42	1.03	1.55	1.74	0.67
	70	0.41	0.67	-	0.76	0.37		70	0.65	1.22	-	1.43	0.63
80	0.37	-	-	0.48	0.31	80	0.68	-	-	0.93	0.52		

Devcan 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.19
Non-Hodgkin Lymphoma

SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends^a
By Race/Ethnicity and Sex

SEER Incidence	SEER 18 Areas ^b			SEER 13 Areas ^b			SEER 9 Areas ^b		
	Rate 2010-2014			Trend 2005-2014 ^c			Trend 2005-2014 ^d		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	19.5	23.7	16.0	-0.6	-0.5	-0.8*	-0.6*	-0.5	-0.9*
White	20.4	24.8	16.9	-0.6	-0.5	-0.8*	-0.7*	-0.5	-0.9*
White Hispanic ^e	18.4	21.6	15.8	0.4*	0.2	0.8*	-	-	-
White Non-Hispanic ^e	20.8	25.4	17.0	-0.6*	-0.5	-0.9*	-	-	-
Black	14.6	17.6	12.2	-1.0*	-0.3	0.2	0.0	-0.5	-1.0
Asian/Pacific Islander	13.5	16.7	11.1	0.2	0.3*	0.2	-	-	-
Amer Ind/Alaska Nat ^f	12.1	13.2	11.1	1.3	0.2	2.1*	-	-	-
Hispanic ^e	17.8	20.7	15.4	0.4*	0.1	0.8*	-	-	-
<u>U.S. Mortality^g</u>									
	Rate 2010-2014			Trend 2005-2014 ^h					
	Rate per 100,000 persons			AAPC (%)					
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females			
All Races	5.9	7.6	4.6	-2.3*	-2.1*	-2.7*			
White	6.1	7.9	4.8	-2.3*	-2.1*	-2.7*			
White Hispanic ^e	5.3	6.6	4.3	-1.2*	-0.7	-2.0*			
White Non-Hispanic ^e	6.2	8.0	4.8	-2.3*	-2.5*	-2.7*			
Black	4.3	5.5	3.5	-2.3*	-2.3*	-2.2*			
Asian/Pacific Islander	4.0	4.9	3.2	-1.9*	-2.0*	-1.7*			
Amer Ind/Alaska Nat									
Total U.S.	3.0	3.9	2.3	-3.5*	-1.7*	-5.1*			
CHSDA Counties	4.2	5.6	3.2	-0.8	-0.5	-4.5*			
Non-CHSDA Counties	1.7	2.1	1.3	-5.6*	-5.2*	-4.7*			
Hispanic ^e	5.0	6.2	4.1	-1.3*	-0.9*	-2.1*			

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry, and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG.

c The 2005-2014 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1992-2014.

d The 2005-2014 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2014.

e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2005-2014 Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

f Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

g US Mortality Files, National Center for Health Statistics, CDC.

h The 2005-2014 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2014.

* The APC is significantly different from zero (p<.05).

Table 19.20
Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates^a, 2010-2014</u>									
California	18.66	22.78	15.29	19.61	23.88	16.06	14.27	16.66	12.21
Greater Bay Area	20.00	24.64	16.17	21.92	26.91	17.73	16.28	19.64	13.25
San Francisco-Oakland	20.04	25.11	15.91	22.13	27.46	17.72	15.73	19.45	12.53
San Jose-Monterey	19.96	23.78	16.70	21.59	25.99	17.76	19.98	20.71	18.38
Los Angeles	18.28	22.16	15.18	19.66	23.72	16.30	14.16	16.58	12.36
Greater California	18.36	22.40	15.04	18.94	23.07	15.52	13.42	15.22	11.67
Connecticut	20.89	25.65	17.22	21.33	26.11	17.62	13.46	17.08	10.82
Detroit	21.49	26.59	17.54	23.31	28.56	19.13	15.48	19.42	12.64
Georgia	17.89	21.85	14.73	18.87	22.85	15.55	14.58	17.88	12.20
Atlanta	18.77	23.31	15.17	20.26	25.28	16.14	16.44	19.47	13.92
Rural Georgia	13.00	13.78	12.24	15.26	16.39	13.64	8.14	-	-
Greater Georgia	17.56	21.33	14.56	18.48	22.20	15.37	13.39	16.76	11.12
Hawaii	18.06	22.05	14.59	21.25	24.12	18.03	-	-	-
Iowa	21.94	26.84	18.13	22.00	26.83	18.26	15.05	18.25	13.11
Kentucky	20.50	25.21	16.73	20.74	25.29	17.09	15.02	20.84	10.74
Louisiana	19.97	23.94	16.73	21.64	25.53	18.38	14.93	18.75	11.98
New Jersey	21.25	25.54	17.93	22.41	26.97	18.82	13.67	15.81	12.11
New Mexico	15.37	17.58	13.47	15.55	17.87	13.56	9.04	12.26	-
Seattle-Puget Sound	21.47	26.47	17.28	22.18	27.16	17.97	18.15	19.91	16.01
Utah	18.87	23.22	15.09	19.03	23.46	15.18	-	-	-
SEER 9 Areas ^b	20.17	24.83	16.40	21.16	25.85	17.30	15.70	19.16	12.96
SEER 13 Areas ^b	19.70	24.12	16.12	20.85	25.40	17.10	15.36	18.56	12.85
SEER 18 Areas ^b	19.47	23.73	16.03	20.42	24.77	16.85	14.56	17.65	12.17

^a Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.21
Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Death Rates^a, 2010-2014</u>									
California	5.58	7.08	4.42	5.98	7.64	4.70	4.35	4.92	3.85
Greater Bay Area	5.40	7.10	4.09	6.00	8.06	4.40	4.82	5.44	4.28
San Francisco-Oakland	5.39	7.19	4.01	5.95	8.14	4.23	4.86	5.42	4.39
San Jose-Monterey	5.41	6.94	4.25	6.09	7.92	4.71	-	-	-
Los Angeles	5.56	6.84	4.58	6.06	7.39	5.03	4.44	5.13	3.86
Greater California	5.64	7.18	4.46	5.94	7.60	4.65	4.04	4.55	3.61
Connecticut	5.45	7.12	4.27	5.57	7.23	4.37	3.66	5.63	2.51
Detroit	6.73	8.83	5.18	7.23	9.35	5.63	5.11	7.08	3.77
Georgia	5.38	7.14	4.12	5.86	7.58	4.58	3.78	5.42	2.72
Atlanta	4.98	7.09	3.55	5.32	7.69	3.64	4.17	5.78	3.19
Rural Georgia	5.58	8.07	3.91	6.89	8.96	-	-	-	-
Greater Georgia	5.54	7.16	4.35	6.03	7.56	4.87	3.56	5.18	2.45
Hawaii	5.23	6.72	3.99	5.79	7.07	4.35	-	-	-
Iowa	6.62	8.73	5.10	6.64	8.75	5.11	6.36	-	-
Kentucky	6.76	9.01	5.10	6.91	9.13	5.26	4.35	7.19	2.41
Louisiana	6.57	8.57	4.99	7.01	8.94	5.45	5.03	6.94	3.60
New Jersey	5.55	7.26	4.37	5.96	7.83	4.62	3.60	4.45	3.12
New Mexico	4.97	5.95	4.15	5.00	5.99	4.16	-	-	-
Seattle-Puget Sound	6.11	7.75	4.86	6.30	7.99	5.00	5.07	5.94	4.07
Utah	5.61	6.76	4.67	5.74	6.91	4.79	-	-	-
SEER 9 Areas ^b	5.80	7.53	4.50	6.09	7.88	4.71	4.59	6.17	3.49
SEER 13 Areas ^b	5.72	7.34	4.50	6.09	7.79	4.77	4.55	5.88	3.59
SEER 18 Areas ^b	5.77	7.44	4.52	6.13	7.87	4.80	4.28	5.62	3.32
Total U.S.	5.88	7.58	4.59	6.13	7.88	4.77	4.29	5.50	3.45

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 19.22
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2010-2014

Males and Females

State	Rate	SE	Rank(CI) ^d	PD
TOTAL U.S.	5.88	0.02		
High Five States				
Kentucky	6.76	0.17	01(01,16)	15.00 ^c
Michigan	6.74	0.11	02(01,12)	14.58
Minnesota	6.67	0.15	03(01,17)	13.49
Iowa	6.62	0.19	04(01,21)	12.67
Louisiana	6.57	0.17	05(01,20)	11.76
Low Five States				
New Hampshire	5.32	0.26	47(18,51)	-9.59
Hawaii	5.23	0.25	48(21,51)	-11.09
Colorado	5.17	0.15	49(31,51)	-11.99
New Mexico	4.97	0.21	50(31,51)	-15.44 ^c
D.C.	4.47	0.40	51(27,51)	-23.95 ^c

State	Rate	SE	Rank(CI) ^d	PD	State	Rate	SE	Rank(CI) ^d	PD
Alabama	5.95	0.15	23(10,39)	1.17	Montana	5.67	0.31	29(05,50)	-3.56
Alaska	5.36	0.49	45(01,51)	-8.87	Nebraska	6.06	0.24	19(02,44)	3.08
Arizona	5.42	0.12	42(26,49)	-7.84	Nevada	5.32	0.20	46(22,51)	-9.57
Arkansas	6.28	0.19	15(01,31)	6.79	New Hampshire	5.32	0.26	47(18,51)	-9.59
California	5.58	0.06	33(25,43)	-5.18	New Jersey	5.55	0.11	37(23,47)	-5.56
Colorado	5.17	0.15	49(31,51)	-11.99	New Mexico	4.97	0.21	50(31,51)	-15.44 ^c
Connecticut	5.45	0.16	40(22,50)	-7.24	New York	5.63	0.07	31(23,42)	-4.17
Delaware	6.02	0.34	20(01,49)	2.45	North Carolina	5.72	0.11	25(19,43)	-2.64
D.C.	4.47	0.40	51(27,51)	-23.95 ^c	North Dakota	5.57	0.37	34(04,51)	-5.20
Florida	5.57	0.07	35(25,45)	-5.27	Ohio	6.55	0.10	07(01,16)	11.35
Georgia	5.38	0.11	44(28,50)	-8.51	Oklahoma	6.48	0.18	09(01,24)	10.14
Hawaii	5.23	0.25	48(21,51)	-11.09	Oregon	6.40	0.17	10(01,24)	8.91
Idaho	6.39	0.28	11(01,35)	8.72	Pennsylvania	6.33	0.09	12(05,21)	7.70
Illinois	5.98	0.09	22(14,30)	1.71	Rhode Island	5.70	0.30	28(05,50)	-3.13
Indiana	6.56	0.14	06(01,18)	11.59	South Carolina	5.56	0.15	36(21,49)	-5.36
Iowa	6.62	0.19	04(01,21)	12.67	South Dakota	5.70	0.34	27(03,51)	-3.07
Kansas	6.07	0.20	18(04,38)	3.21	Tennessee	6.30	0.13	14(03,24)	7.23
Kentucky	6.76	0.17	01(01,16)	15.00 ^c	Texas	5.71	0.07	26(22,39)	-2.94
Louisiana	6.57	0.17	05(01,20)	11.76	Utah	5.61	0.23	32(14,50)	-4.57
Maine	6.32	0.27	13(01,36)	7.54	Vermont	6.00	0.40	21(01,50)	1.98
Maryland	5.41	0.13	43(25,50)	-7.96	Virginia	5.67	0.12	30(19,46)	-3.59
Massachusetts	5.52	0.12	38(23,48)	-6.11	Washington	6.17	0.13	17(06,28)	4.86
Michigan	6.74	0.11	02(01,12)	14.58	West Virginia	6.51	0.23	08(01,26)	10.78
Minnesota	6.67	0.15	03(01,17)	13.49	Wisconsin	6.23	0.14	16(04,26)	5.94
Mississippi	5.44	0.19	41(21,50)	-7.56	Wyoming	5.50	0.44	39(01,51)	-6.48
Missouri	5.90	0.13	24(13,38)	0.34					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant ($p < .0002$).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

^d Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 19.23
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2010-2014

Males

State	Rate	SE	Rank(CI) ^d	PD
TOTAL U.S.	7.58	0.03		
High Five States				
Kentucky	9.01	0.31	01(01,14)	18.82 ^c
Michigan	8.78	0.19	02(01,12)	15.80 ^c
Iowa	8.73	0.33	03(01,21)	15.16 ^c
Indiana	8.59	0.24	04(01,18)	13.33
Louisiana	8.57	0.30	05(01,21)	13.03
Low Five States				
Hawaii	6.72	0.43	47(14,51)	-11.31
Wyoming	6.61	0.72	48(03,51)	-12.86
Colorado	6.58	0.26	49(27,51)	-13.23
D.C.	6.10	0.73	50(08,51)	-19.60 ^c
New Mexico	5.95	0.34	51(39,51)	-21.46 ^c

State	Rate	SE	Rank(CI) ^d	PD	State	Rate	SE	Rank(CI) ^d	PD
Alabama	7.55	0.27	23(09,45)	-0.47	Montana	7.55	0.53	22(01,50)	-0.36
Alaska	7.07	0.83	39(01,51)	-6.79	Nebraska	7.26	0.40	31(07,50)	-4.29
Arizona	6.81	0.20	45(26,50)	-10.17	Nevada	6.87	0.34	42(16,51)	-9.36
Arkansas	7.63	0.33	20(05,46)	0.61	New Hampshire	6.84	0.46	44(11,51)	-9.78
California	7.08	0.09	38(26,45)	-6.57	New Jersey	7.26	0.19	30(17,46)	-4.24
Colorado	6.58	0.26	49(27,51)	-13.23	New Mexico	5.95	0.34	51(39,51)	-21.46 ^c
Connecticut	7.12	0.28	36(15,50)	-6.06	New York	7.28	0.13	29(19,44)	-3.92
Delaware	7.85	0.59	18(01,50)	3.50	North Carolina	7.43	0.19	27(14,43)	-1.94
D.C.	6.10	0.73	50(08,51)	-19.60 ^c	North Dakota	6.95	0.63	41(03,51)	-8.31
Florida	7.21	0.11	33(22,44)	-4.91	Ohio	8.47	0.17	07(01,17)	11.71
Georgia	7.14	0.20	35(19,48)	-5.86	Oklahoma	8.33	0.31	08(01,28)	9.94
Hawaii	6.72	0.43	47(14,51)	-11.31	Oregon	8.24	0.29	11(01,31)	8.72
Idaho	7.95	0.47	16(01,47)	4.83	Pennsylvania	8.26	0.16	10(03,20)	8.96
Illinois	7.85	0.17	17(08,29)	3.54	Rhode Island	6.85	0.51	43(07,51)	-9.71
Indiana	8.59	0.24	04(01,18)	13.33	South Carolina	7.19	0.26	34(15,49)	-5.16
Iowa	8.73	0.33	03(01,21)	15.16 ^c	South Dakota	7.51	0.59	25(01,51)	-0.94
Kansas	7.66	0.34	19(04,46)	1.01	Tennessee	8.31	0.24	09(01,23)	9.65
Kentucky	9.01	0.31	01(01,14)	18.82 ^c	Texas	7.36	0.13	28(18,41)	-2.85
Louisiana	8.57	0.30	05(01,21)	13.03	Utah	6.76	0.38	46(15,51)	-10.81
Maine	7.59	0.46	21(02,49)	0.10	Vermont	8.02	0.71	14(01,50)	5.81
Maryland	7.11	0.24	37(17,49)	-6.17	Virginia	7.46	0.21	26(12,44)	-1.57
Massachusetts	7.07	0.21	40(19,49)	-6.80	Washington	7.95	0.23	15(04,32)	4.90
Michigan	8.78	0.19	02(01,12)	15.80 ^c	West Virginia	8.09	0.40	12(01,41)	6.77
Minnesota	8.57	0.26	06(01,20)	13.02	Wisconsin	8.07	0.24	13(03,29)	6.39
Mississippi	7.25	0.34	32(10,49)	-4.40	Wyoming	6.61	0.72	48(03,51)	-12.86
Missouri	7.51	0.23	24(11,44)	-0.92					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant (p<=.0002).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

^d Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 19.24
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2010-2014

Females

State	Rate	SE	Rank(CI) ^d	PD
TOTAL U.S.	4.59	0.02		
High Five States				
West Virginia	5.35	0.29	01(01,28)	16.50 ^c
Maine	5.33	0.33	02(01,36)	16.08 ^c
Arkansas	5.23	0.24	03(01,28)	13.99
Michigan	5.19	0.13	04(01,19)	13.02
Minnesota	5.18	0.18	05(01,24)	12.87
Low Five States				
Colorado	4.03	0.17	47(26,51)	-12.16
Hawaii	3.99	0.29	48(15,51)	-13.03
Nevada	3.99	0.24	49(22,51)	-13.06
Alaska	3.69	0.56	50(02,51)	-19.62 ^c
D.C.	3.30	0.45	51(21,51)	-28.05 ^c

State	Rate	SE	Rank(CI) ^d	PD	State	Rate	SE	Rank(CI) ^d	PD
Alabama	4.78	0.18	19(03,39)	4.27	Montana	4.12	0.36	45(04,51)	-10.17
Alaska	3.69	0.56	50(02,51)	-19.62 ^c	Nebraska	5.12	0.30	07(01,39)	11.48
Arizona	4.25	0.15	39(21,49)	-7.30	Nevada	3.99	0.24	49(22,51)	-13.06
Arkansas	5.23	0.24	03(01,28)	13.99	New Hampshire	4.13	0.31	44(07,51)	-9.94
California	4.42	0.07	31(23,42)	-3.59	New Jersey	4.37	0.12	34(20,47)	-4.83
Colorado	4.03	0.17	47(26,51)	-12.16	New Mexico	4.15	0.26	43(15,51)	-9.59
Connecticut	4.27	0.19	38(18,50)	-7.00	New York	4.43	0.08	30(20,43)	-3.53
Delaware	4.63	0.40	24(01,51)	0.88	North Carolina	4.49	0.12	28(15,44)	-2.14
D.C.	3.30	0.45	51(21,51)	-28.05 ^c	North Dakota	4.53	0.45	27(01,51)	-1.33
Florida	4.22	0.08	40(28,48)	-7.96	Ohio	5.11	0.12	08(01,21)	11.40
Georgia	4.12	0.13	46(27,50)	-10.18	Oklahoma	5.00	0.21	12(01,34)	8.89
Hawaii	3.99	0.29	48(15,51)	-13.03	Oregon	4.92	0.20	14(01,36)	7.20
Idaho	5.06	0.34	11(01,45)	10.38	Pennsylvania	4.89	0.10	15(05,27)	6.58
Illinois	4.63	0.11	25(12,38)	0.83	Rhode Island	4.70	0.35	21(01,50)	2.45
Indiana	5.12	0.16	06(01,24)	11.51	South Carolina	4.35	0.17	36(15,49)	-5.10
Iowa	5.10	0.22	09(01,30)	11.15	South Dakota	4.32	0.40	37(02,51)	-5.82
Kansas	4.86	0.23	17(01,42)	5.84	Tennessee	4.79	0.15	18(04,36)	4.31
Kentucky	5.10	0.19	10(01,27)	11.05	Texas	4.44	0.08	29(21,43)	-3.20
Louisiana	4.99	0.19	13(01,32)	8.84	Utah	4.67	0.28	23(01,49)	1.84
Maine	5.33	0.33	02(01,36)	16.08 ^c	Vermont	4.40	0.46	32(01,51)	-4.11
Maryland	4.22	0.16	41(21,50)	-8.05	Virginia	4.36	0.14	35(19,48)	-5.02
Massachusetts	4.40	0.14	33(18,47)	-4.15	Washington	4.78	0.16	20(04,37)	4.16
Michigan	5.19	0.13	04(01,19)	13.02	West Virginia	5.35	0.29	01(01,28)	16.50 ^c
Minnesota	5.18	0.18	05(01,24)	12.87	Wisconsin	4.86	0.16	16(03,35)	5.91
Mississippi	4.18	0.22	42(17,51)	-9.00	Wyoming	4.56	0.53	26(01,51)	-0.64
Missouri	4.68	0.16	22(07,40)	1.99					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant ($p < .0002$).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

^d Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.25
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2014
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 ^e	0 to <39 ^e	>=39 ^g	Complete ^h	
Race	Sex											
All Races ^b	Both Sexes	247,549	171,171	107,339	61,534	32,564	19,328	615,303	653,661	8,335	661,996	
	Males	134,164	89,969	55,681	31,794	16,734	10,167	325,886	346,187	4,460	350,647	
	Females	113,385	81,202	51,658	29,740	15,830	9,161	289,417	307,474	3,875	311,349	
White ^b	Both Sexes	213,854	150,511	94,695	54,077	29,075	17,504	537,797	572,570	8,781	581,351	
	Males	116,394	79,369	49,345	27,844	14,948	9,226	285,660	304,105	5,049	309,154	
	Females	97,460	71,142	45,350	26,233	14,127	8,278	252,137	268,465	3,732	272,197	
Black ^b	Both Sexes	20,241	13,137	8,292	4,757	2,078	1,220	48,274	50,604	724	51,328	
	Males	10,423	6,541	4,121	2,515	1,036	641	24,517	25,727	320	26,047	
	Females	9,818	6,596	4,171	2,242	1,042	579	23,757	24,877	404	25,281	
Asian/ Pacific Islander ^c	Both Sexes	7,657	4,695	2,905	1,605	+	+	17,244	+	+	+	
	Males	4,140	2,454	1,466	835	+	+	9,081	+	+	+	
	Females	3,517	2,241	1,439	770	+	+	8,163	+	+	+	
Hispanic ^d	Both Sexes	19,630	11,818	7,221	3,986	+	+	43,564	+	+	+	
	Males	10,215	6,134	3,741	2,154	+	+	22,702	+	+	+	
	Females	9,415	5,684	3,480	1,832	+	+	20,862	+	+	+	

Estimated prevalence percent^a on January 1, 2014, of the SEER^c population diagnosed in the previous 22 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted ^f	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races ^c	Both Sexes	0.1698%	0.0032%	0.0126%	0.0269%	0.0493%	0.1043%	0.2167%	0.4262%	0.7404%	0.9295%	0.1595%
	Males	0.1825%	0.0039%	0.0175%	0.0329%	0.0570%	0.1217%	0.2481%	0.4839%	0.8492%	1.1279%	0.1858%
	Females	0.1574%	0.0025%	0.0074%	0.0206%	0.0415%	0.0871%	0.1865%	0.3741%	0.6513%	0.8100%	0.1374%
White ^c	Both Sexes	0.1923%	0.0031%	0.0130%	0.0286%	0.0505%	0.1109%	0.2320%	0.4639%	0.8169%	1.0158%	0.1727%
	Males	0.2057%	0.0040%	0.0184%	0.0350%	0.0582%	0.1300%	0.2640%	0.5217%	0.9297%	1.2247%	0.2001%
	Females	0.1790%	0.0023%	0.0073%	0.0217%	0.0423%	0.0912%	0.2002%	0.4098%	0.7220%	0.8882%	0.1491%
Black ^c	Both Sexes	0.1058%	0.0034%	0.0111%	0.0255%	0.0577%	0.1013%	0.1899%	0.3178%	0.4713%	0.4945%	0.1189%
	Males	0.1132%	0.0032%	0.0149%	0.0327%	0.0698%	0.1152%	0.2197%	0.3730%	0.5095%	0.5934%	0.1370%
	Females	0.0991%	0.0035%	0.0071%	0.0184%	0.0470%	0.0892%	0.1639%	0.2746%	0.4446%	0.4455%	0.1047%
Asian/ Pacific Islander ^c	Both Sexes	0.1024%	0.0032%	0.0118%	0.0200%	0.0339%	0.0655%	0.1367%	0.2558%	0.4282%	0.5914%	0.0989%
	Males	0.1117%	0.0040%	0.0151%	0.0235%	0.0375%	0.0734%	0.1587%	0.2924%	0.5153%	0.7550%	0.1176%
	Females	0.0938%	0.0025%	0.0083%	0.0164%	0.0305%	0.0584%	0.1177%	0.2260%	0.3602%	0.4909%	0.0844%
Hispanic ^d	Both Sexes	0.0820%	0.0023%	0.0107%	0.0209%	0.0354%	0.0800%	0.1682%	0.3344%	0.5519%	0.7044%	0.1220%
	Males	0.0843%	0.0023%	0.0145%	0.0254%	0.0407%	0.0913%	0.1829%	0.3652%	0.5875%	0.7970%	0.1347%
	Females	0.0797%	0.0023%	0.0067%	0.0160%	0.0297%	0.0682%	0.1540%	0.3077%	0.5254%	0.6484%	0.1112%

^a US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

^e Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^{g h i} (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 19.26
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a
SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2005-2014

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	36.0	312,514	-0.3*	6.0	14,191	0.4	23.6	132,078	-0.6*	161.6	166,245	-0.3
1 Hodgkin Lymphoma	2.7	23,244	-1.8*	1.2	2,913	-1.0	3.1	16,192	-1.6*	4.0	4,139	-2.8*
2 Non-Hodgkin lymphoma	32.3	280,967	-0.1	4.7	11,140	0.6	19.9	113,078	-0.3*	152.5	156,749	-0.1
2(a) Non-Hodgkin lymphoma, B-cell	29.9	259,802	0.1	3.7	8,784	2.2*	18.0	102,702	-0.1	144.3	148,316	0.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.4	12,151	3.1*	3.0	7,076	2.2*	0.7	3,772	4.4*	1.3	1,303	4.8*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	26.9	234,405	-0.3	0.7	1,596	2.3*	16.6	94,651	-0.5*	134.4	138,158	-0.2
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.6	57,852	-1.3*	0.0	28	-	3.3	19,692	-1.3*	37.0	38,132	-1.4*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	5.8	50,597	-1.6*	0.0	23	-	2.9	17,032	-1.5*	32.6	33,542	-1.7*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	203	-4.3*	-	-	-	0.0	53	-	0.1	145	-5.1*
2(a) 2.1.3. Mantle-cell lymphoma	0.8	7,052	1.0	-	-	-	0.4	2,607	0.4	4.3	4,445	1.3
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.6	5,464	-1.1	-	-	-	0.3	1,642	-2.3*	3.7	3,819	-0.6
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	2,470	-0.6	-	-	-	0.1	746	-1.5	1.7	1,723	-0.3
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.3	2,994	-1.4*	-	-	-	0.1	896	-2.9*	2.0	2,096	-0.9
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	7.0	60,663	0.4*	0.3	658	1.1	4.6	25,771	0.1	33.3	34,234	0.6*
2(a) 2.3.1. DLBCL, NOS ^c	6.9	59,939	0.3	0.3	620	0.8	4.5	25,203	-0.1	33.2	34,116	0.6*
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	98	-	-	-	-	0.0	46	-	0.1	52	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	115	-	-	-	-	0.0	82	-	0.0	33	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.1	511	7.7*	0.0	38	-	0.1	440	8.0*	0.0	33	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	3,468	-1.0	0.3	718	3.6	0.4	1,975	-2.6	0.8	775	-1.3
2(a) 2.5. Marginal-zone lymphoma (MZL)	2.0	17,305	0.1	0.0	102	-	1.3	7,192	0.6	9.7	10,011	-0.2
2(a) 2.5.1. Splenic MZL	0.2	1,539	-1.2	-	-	-	0.1	591	-2.2	0.9	948	-0.6
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.2	10,333	1.2	0.0	68	-	0.8	4,599	1.5*	5.5	5,666	0.9
2(a) 2.5.3. Nodal MZL	0.6	5,433	-1.6	0.0	34	-	0.3	2,002	-0.6	3.3	3,397	-2.1
2(a) 2.6. Follicular lymphoma	3.6	31,383	-2.1*	0.0	73	-	2.8	15,826	-2.5*	15.0	15,484	-1.6*
2(a) 2.7. Hairy-cell leukemia	0.3	2,588	-0.2	-	-	-	0.3	1,635	0.1	0.9	953	-0.7
2(a) 2.8. Plasma cell neoplasms	6.4	55,644	1.0*	-	-	-	3.6	20,902	1.0*	33.8	34,729	1.0*
2(a) 2.8.1. Plasmacytoma	0.4	3,554	1.5	-	-	-	0.3	1,734	2.1*	1.8	1,809	0.9
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	6.0	52,090	1.0*	-	-	-	3.3	19,168	0.9*	32.1	32,920	1.0*
2(a) 2.9. Heavy chain disease	0.0	38	-	-	-	-	0.0	16	-	0.0	21	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.5	13,246	5.4*	0.0	112	-	0.8	4,279	5.2*	8.6	8,855	5.5*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.26 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2005-2014

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.2	18,706	0.4	0.8	1,841	3.1*	1.8	9,590	0.0	7.1	7,275	0.2
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.1	699	-	0.1	330	-	0.1	311	-	0.1	58	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	2.1	17,930	1.7*	0.6	1,508	10.3*	1.7	9,238	1.2*	7.0	7,184	0.6
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.5	4,565	1.6*	0.1	134	-	0.5	2,663	1.3	1.7	1,768	1.3*
2(b) 2.1.1. Mycosis fungoides	0.5	4,422	1.4*	0.1	134	-	0.5	2,615	1.1	1.6	1,673	1.2*
2(b) 2.1.2. Sezary syndrome	0.0	143	-	-	-	-	0.0	48	-	0.1	95	-
2(b) 2.2. Peripheral T-cell lymphoma	1.2	10,118	0.1	0.2	410	1.9	0.9	5,062	-0.4	4.5	4,646	0.3
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.4	3,635	1.6*	0.0	72	-	0.3	1,716	1.9*	1.8	1,847	1.3
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.2	1,320	1.1	-	-	-	0.1	508	-1.7	0.8	809	2.6
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	134	-0.7	0.0	26	-	0.0	79	-	0.0	29	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	1,896	-2.8*	0.1	233	0.4	0.2	1,076	-2.6	0.6	587	-4.4*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	90	-	-	-	-	0.0	67	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	121	-	-	-	-	0.0	53	-	0.1	68	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.2	2,023	0.6	0.0	35	-	0.2	1,079	0.7	0.9	909	0.3
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	899	-3.4*	0.0	29	-	0.1	484	-5.2*	0.4	386	-1.9
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.2	2,063	12.6*	0.4	940	14.8*	0.2	835	11.8*	0.3	288	6.3*
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	718	0.8	0.0	22	-	0.1	493	1.2	0.2	203	1.4
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	149	-	-	-	-	0.0	58	-	0.1	90	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	317	3.9	-	-	-	0.0	127	-	0.2	189	4.3*
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	77	-	-	-	-	0.0	41	-	0.0	33	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.3	2,459	-24.7*	0.2	515	-	0.1	786	-	1.1	1,158	-
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.1	964	-26.0*	0.2	500	-	0.0	249	-	0.2	215	-
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	89	-	-	-	-	0.0	26	-	0.1	62	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.2	1,406	-	-	-	-	0.1	511	-	0.9	881	-
2(*) 1. Total precursor lymphoma/leukemia ^d	1.6	13,814	-0.7	3.4	7,906	-1.3*	0.8	4,332	0.1	1.5	1,576	0.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	334	29.8*	-	-	-	0.0	166	-	0.2	160	-
4 Lymphoid neoplasm, NOS ^c	0.9	7,969	-5.0*	0.1	130	-	0.5	2,642	-5.5*	5.0	5,197	-5.1*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a
SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2005-2014

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	44.6	174,877	-0.3	6.8	8,243	0.3	28.1	77,233	-0.7*	206.9	89,401	-0.1
1 Hodgkin Lymphoma	3.1	12,825	-1.7*	1.3	1,591	-0.7	3.5	9,013	-1.5*	5.0	2,221	-2.9*
2 Non-Hodgkin lymphoma	40.4	157,677	-0.1	5.5	6,568	0.4	24.0	66,562	-0.5*	195.5	84,547	0.1
2(a) Non-Hodgkin lymphoma, B-cell	37.3	145,175	0.2	4.2	5,010	2.1*	21.7	60,337	-0.3	184.7	79,828	0.3
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.6	6,570	3.0*	3.2	3,831	1.7	0.8	2,099	4.5*	1.5	640	5.8*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	33.8	131,530	-0.3	0.9	1,096	3.2*	20.0	55,770	-0.7*	172.6	74,664	-0.1
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	9.2	35,489	-1.4*	0.0	17	-	4.5	12,866	-1.3*	52.4	22,606	-1.4*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	7.9	30,366	-1.7*	-	-	-	3.8	10,896	-1.6*	45.1	19,455	-1.7*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	139	-4.2*	-	-	-	0.0	38	-	0.2	99	-
2(a) 2.1.3. Mantle-cell lymphoma	1.3	4,984	0.8	-	-	-	0.7	1,932	0.2	7.0	3,052	1.0
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.8	3,172	-1.4	-	-	-	0.3	939	-2.2	5.2	2,232	-1.1
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.4	1,361	-1.0	-	-	-	0.1	398	-2.5	2.2	963	-0.5
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.5	1,811	-1.7*	-	-	-	0.2	541	-2.0	3.0	1,269	-1.6
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	8.6	33,390	0.6*	0.3	385	3.5	5.7	15,468	-0.2	40.8	17,537	1.0*
2(a) 2.3.1. DLBCL, NOS ^c	8.5	33,043	0.5	0.3	370	2.8	5.6	15,205	-0.3	40.7	17,468	1.0*
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	47	-	-	-	-	0.0	23	-	0.1	24	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	105	-	-	-	-	0.0	79	-	0.1	26	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	195	-	-	-	-	0.1	161	-	0.0	19	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.6	2,525	-1.1	0.5	558	3.1	0.6	1,506	-3.1*	1.1	461	0.1
2(a) 2.5. Marginal-zone lymphoma (MZL)	2.1	8,132	-0.2	0.1	70	-	1.2	3,475	0.0	10.6	4,587	-0.4
2(a) 2.5.1. Splenic MZL	0.2	733	-0.9	-	-	-	0.1	291	-1.9	1.0	442	-0.4
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.2	4,736	0.7	0.0	41	-	0.8	2,155	1.0	5.8	2,540	0.4
2(a) 2.5.3. Nodal MZL	0.7	2,663	-1.6	0.0	29	-	0.4	1,029	-1.6	3.7	1,605	-1.6
2(a) 2.6. Follicular lymphoma	3.9	15,720	-1.9*	0.0	59	-	3.0	8,205	-2.9*	16.9	7,456	-1.1
2(a) 2.7. Hairy-cell leukemia	0.5	2,068	-0.6	-	-	-	0.5	1,329	-0.2	1.7	739	-1.0
2(a) 2.8. Plasma cell neoplasms	8.0	31,009	1.2*	-	-	-	4.2	11,973	1.0*	44.0	19,031	1.3*
2(a) 2.8.1. Plasmacytoma	0.6	2,195	0.7	-	-	-	0.4	1,116	1.2	2.5	1,075	0.4
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	7.5	28,814	1.2*	-	-	-	3.8	10,857	0.9*	41.5	17,956	1.3*
2(a) 2.9. Heavy chain disease	0.0	25	-	-	-	-	-	-	-	-	-	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.9	7,075	5.8*	0.1	83	-	0.9	2,468	6.0*	10.6	4,524	5.7*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2005-2014

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.8	11,160	0.3	1.1	1,264	1.5	2.1	5,735	0.0	9.5	4,161	0.4
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.1	486	-	0.2	240	-	0.1	213	-	0.1	33	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	2.6	10,633	1.7*	0.8	1,022	8.9*	2.1	5,503	1.3*	9.4	4,108	0.7
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.6	2,607	1.5*	0.1	71	-	0.6	1,497	0.9	2.4	1,039	1.2
2(b) 2.1.1. Mycosis fungoides	0.6	2,523	1.3	0.1	71	-	0.6	1,468	0.8	2.2	984	1.0
2(b) 2.1.2. Sezary syndrome	0.0	84	-	-	-	-	0.0	29	-	0.1	55	-
2(b) 2.2. Peripheral T-cell lymphoma	1.5	5,944	0.0	0.2	248	-1.7	1.1	3,045	-0.3	6.1	2,651	0.5
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.6	2,186	1.2	0.0	43	-	0.4	1,090	1.8	2.4	1,053	0.8
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.2	710	3.0*	-	-	-	0.1	295	0.7	0.9	412	4.1*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	46	-	-	-	-	0.0	25	-	-	-	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.3	1,159	-3.1*	0.1	147	-	0.3	665	-3.0	0.8	347	-3.4*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	62	-	-	-	-	0.0	45	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	68	-	-	-	-	0.0	30	-	0.1	38	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.3	1,190	0.1	0.0	19	-	0.2	633	-0.6	1.2	538	0.8
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	523	-3.8	0.0	17	-	0.1	262	-5.2*	0.6	244	-2.3
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.3	1,372	12.2*	0.6	684	12.4*	0.2	541	13.0*	0.3	147	-
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	462	-0.3	0.0	18	-	0.1	322	0.3	0.3	122	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	67	-	-	-	-	0.0	21	-	0.1	46	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	181	6.7*	-	-	-	0.0	77	-	0.2	103	-
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	41	-	-	-	-	0.0	19	-	0.0	20	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.3	1,342	-	0.2	294	-	0.2	490	-	1.3	558	-
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.1	555	-	0.2	284	-	0.1	145	-	0.3	126	-
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	52	-	-	-	-	-	-	-	0.1	37	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.2	735	-	-	-	-	0.1	331	-	0.9	395	-
2(*) 1. Total precursor lymphoma/leukemia ^d	1.8	7,611	-1.2*	3.6	4,355	-2.2*	0.9	2,457	-0.3	1.8	799	1.0
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	185	-	-	-	-	0.0	98	-	0.2	82	-
4 Lymphoid neoplasm, NOS ^c	1.1	4,190	-4.9*	0.1	79	-	0.6	1,560	-6.3*	6.1	2,551	-4.8*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

- Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2005-2014

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	29.1	137,637	-0.5*	5.2	5,948	0.6	19.3	54,845	-0.4	129.2	76,844	-0.7*
1 Hodgkin Lymphoma	2.4	10,419	-1.9*	1.1	1,322	-1.5	2.8	7,179	-1.7*	3.3	1,918	-2.8*
2 Non-Hodgkin lymphoma	25.9	123,290	-0.2	4.0	4,572	1.1	16.0	46,516	0.0	121.6	72,202	-0.5*
2(a) Non-Hodgkin lymphoma, B-cell	24.0	114,627	0.0	3.3	3,774	2.3*	14.5	42,365	0.2	115.3	68,488	-0.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.3	5,581	3.3*	2.8	3,245	2.7*	0.6	1,673	4.3*	1.1	663	3.7
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	21.4	102,875	-0.4*	0.4	500	0.2	13.3	38,881	-0.2	107.0	63,494	-0.6*
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	4.6	22,363	-1.5*	-	-	-	2.2	6,826	-1.2	25.9	15,526	-1.7*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	4.2	20,231	-1.8*	-	-	-	2.0	6,136	-1.4*	23.5	14,087	-2.0*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	64	-	-	-	-	-	-	-	0.1	46	-
2(a) 2.1.3. Mantle-cell lymphoma	0.4	2,068	1.4	-	-	-	0.2	675	0.9	2.4	1,393	1.6
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.5	2,292	-1.0	-	-	-	0.2	703	-2.5	2.7	1,587	-0.4
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.2	1,109	-0.2	-	-	-	0.1	348	0.0	1.3	760	-0.3
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.2	1,183	-1.6*	-	-	-	0.1	355	-4.3*	1.4	827	-0.5
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	5.7	27,273	0.2	0.2	273	-2.1	3.6	10,303	0.4	28.1	16,697	0.1
2(a) 2.3.1. DLBCL, NOS ^c	5.7	26,896	0.0	0.2	250	-1.9	3.5	9,998	0.1	28.0	16,648	0.0
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	51	-	-	-	-	0.0	23	-	0.0	28	-
2(a) 2.3.3. Primary effusion lymphoma	-	-	-	-	-	-	-	-	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.1	316	8.4*	0.0	23	-	0.1	279	9.3*	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.2	943	-0.9	0.1	160	-	0.2	469	-0.8	0.5	314	-4.5
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	9,173	0.4	0.0	32	-	1.3	3,717	1.1*	9.2	5,424	-0.1
2(a) 2.5.1. Splenic MZL	0.2	806	-1.2	-	-	-	0.1	300	-2.6	0.9	506	-0.4
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.2	5,597	1.6*	0.0	27	-	0.8	2,444	1.9*	5.3	3,126	1.3
2(a) 2.5.3. Nodal MZL	0.6	2,770	-1.6*	-	-	-	0.3	973	0.4	3.0	1,792	-2.5*
2(a) 2.6. Follicular lymphoma	3.3	15,663	-2.2*	-	-	-	2.6	7,621	-2.2*	13.7	8,028	-2.2*
2(a) 2.7. Hairy-cell leukemia	0.1	520	0.7	-	-	-	0.1	306	1.8	0.4	214	-1.6
2(a) 2.8. Plasma cell neoplasms	5.1	24,635	0.7	-	-	-	3.0	8,929	1.1	26.5	15,698	0.5
2(a) 2.8.1. Plasmacytoma	0.3	1,359	2.5*	-	-	-	0.2	618	3.9*	1.2	734	1.3
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	4.8	23,276	0.6	-	-	-	2.8	8,311	0.9	25.3	14,964	0.5
2(a) 2.9. Heavy chain disease	-	-	-	-	-	-	-	-	-	-	-	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.3	6,171	4.8*	0.0	29	-	0.6	1,811	4.1*	7.2	4,331	5.1*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2005-2014

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	1.6	7,546	0.5	0.5	577	6.6*	1.4	3,855	0.0	5.3	3,114	-0.1
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.0	213	-	0.1	90	-	0.0	98	-	0.0	25	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.6	7,297	1.5*	0.4	486	13.3*	1.4	3,735	1.0	5.2	3,076	0.2
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.4	1,958	1.6	0.1	63	-	0.4	1,166	1.8	1.2	729	1.2
2(b) 2.1.1. Mycosis fungoides	0.4	1,899	1.5	0.1	63	-	0.4	1,147	1.6	1.2	689	1.3
2(b) 2.1.2. Sezary syndrome	0.0	59	-	-	-	-	0.0	19	-	0.1	40	-
2(b) 2.2. Peripheral T-cell lymphoma	0.9	4,174	0.1	0.1	162	-	0.7	2,017	-0.5	3.4	1,995	0.0
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.3	1,449	2.1*	0.0	29	-	0.2	626	2.0	1.3	794	1.9
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	610	-1.0	-	-	-	0.1	213	-4.8*	0.7	397	1.0
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	88	-	0.0	17	-	0.0	54	-	0.0	17	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	737	-2.4*	0.1	86	-	0.2	411	-1.9	0.4	240	-5.9*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	28	-	-	-	-	0.0	22	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	53	-	-	-	-	0.0	23	-	0.1	30	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.2	833	1.6*	0.0	16	-	0.2	446	2.5*	0.6	371	-0.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	376	-3.3	-	-	-	0.1	222	-5.3	0.2	142	-2.3
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.2	691	13.2*	0.2	256	-	0.1	294	9.4*	0.2	141	-
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	256	2.9	-	-	-	0.1	171	-	0.1	81	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	82	-	-	-	-	0.0	37	-	0.1	44	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	136	-	-	-	-	0.0	50	-	0.1	86	-
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	36	-	-	-	-	0.0	22	-	-	-	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.2	1,117	-	0.2	221	-	0.1	296	-	1.0	600	-
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.1	409	-	0.2	216	-	0.0	104	-	0.1	89	-
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	37	-	-	-	-	-	-	-	0.0	25	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.1	671	-	-	-	-	0.1	180	-	0.8	486	-
2(*) 1. Total precursor lymphoma/leukemia ^d	1.5	6,203	-0.1	3.1	3,551	-0.2	0.7	1,875	0.8	1.3	777	-1.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	149	-	-	-	-	0.0	68	-	0.1	78	-
4 Lymphoid neoplasm, NOS ^c	0.8	3,779	-4.9*	0.0	51	-	0.4	1,082	-4.3*	4.2	2,646	-5.5*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.29
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	178,161	70.2 (69.9 , 70.5)	90.2 (89.5 , 90.9)	77.8 (77.4 , 78.1)	59.8 (59.3 , 60.3)			
1 Hodgkin Lymphoma	14,839	86.4 (85.7 , 87.1)	96.6 (95.5 , 97.4)	90.0 (89.3 , 90.7)	56.7 (53.7 , 59.7)			
2 Non-Hodgkin lymphoma	159,174	69.1 (68.8 , 69.4)	88.5 (87.7 , 89.3)	76.2 (75.8 , 76.6)	60.4 (59.9 , 61.0)			
2(a) Non-Hodgkin lymphoma, B-cell	147,279	69.4 (69.1 , 69.8)	89.2 (88.2 , 90.0)	76.9 (76.5 , 77.3)	61.0 (60.4 , 61.5)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	8,130	68.6 (67.4 , 69.7)	88.7 (87.6 , 89.6)	39.3 (36.9 , 41.7)	18.0 (14.5 , 21.8)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	131,742	69.6 (69.3 , 70.0)	91.3 (89.4 , 93.0)	78.4 (78.0 , 78.8)	61.4 (60.8 , 61.9)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	31,636	79.1 (78.4 , 79.8)	- (- , -)	87.1 (86.3 , 87.9)	73.6 (72.4 , 74.6)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	27,738	82.1 (81.3 , 82.8)	- (- , -)	90.0 (89.1 , 90.8)	76.7 (75.5 , 77.9)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	90	51.2 (37.2 , 63.6)	- (- , -)	63.4 (42.0 , 78.7)	41.7 (23.8 , 58.7)			
2(a) 2.1.3. Mantle-cell lymphoma	3,808	57.9 (55.7 , 60.1)	- (- , -)	68.8 (65.8 , 71.5)	49.1 (45.8 , 52.3)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,893	81.6 (79.0 , 83.8)	- (- , -)	88.8 (85.8 , 91.2)	77.2 (73.5 , 80.5)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,314	77.4 (73.5 , 80.8)	- (- , -)	84.1 (79.1 , 87.9)	73.4 (67.8 , 78.2)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,579	85.1 (81.6 , 88.0)	- (- , -)	92.7 (88.7 , 95.3)	80.4 (75.2 , 84.6)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	34,173	62.3 (61.6 , 62.9)	89.6 (86.2 , 92.2)	71.9 (71.1 , 72.7)	52.4 (51.3 , 53.4)			
2(a) 2.3.1. DLBCL, NOS ^c	33,713	62.1 (61.4 , 62.8)	90.1 (86.6 , 92.6)	71.8 (70.9 , 72.6)	52.4 (51.3 , 53.4)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	61	50.1 (34.4 , 63.9)	- (- , -)	51.0 (31.9 , 67.2)	49.5 (25.4 , 69.7)			
2(a) 2.3.3. Primary effusion lymphoma	51	22.0 (9.2 , 38.2)	- (- , -)	19.6 (6.7 , 37.4)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	348	87.6 (82.5 , 91.2)	- (- , -)	89.3 (84.1 , 92.8)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	2,244	62.5 (60.2 , 64.6)	91.2 (88.1 , 93.5)	58.5 (55.6 , 61.4)	39.9 (34.4 , 45.3)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	9,606	90.0 (88.8 , 91.0)	98.6 (90.2 , 99.8)	93.5 (92.3 , 94.5)	86.5 (84.4 , 88.4)			
2(a) 2.5.1. Splenic MZL	841	84.4 (79.6 , 88.1)	- (- , -)	84.5 (78.6 , 88.8)	84.1 (76.3 , 89.5)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	5,861	94.5 (93.0 , 95.7)	97.8 (85.5 , 99.7)	96.2 (94.8 , 97.2)	92.6 (89.6 , 94.7)			
2(a) 2.5.3. Nodal MZL	2,904	82.6 (80.1 , 84.7)	- (- , -)	89.8 (87.2 , 91.9)	76.7 (72.9 , 80.1)			
2(a) 2.6. Follicular lymphoma	17,820	87.7 (86.9 , 88.4)	97.4 (81.9 , 99.7)	92.2 (91.5 , 92.9)	81.5 (79.9 , 83.0)			
2(a) 2.7. Hairy-cell leukemia	1,562	93.5 (90.8 , 95.4)	- (- , -)	96.7 (94.5 , 98.1)	85.1 (77.2 , 90.5)			
2(a) 2.8. Plasma cell neoplasms	31,780	49.5 (48.7 , 50.2)	- (- , -)	62.2 (61.1 , 63.3)	39.5 (38.5 , 40.6)			
2(a) 2.8.1. Plasmacytoma	1,954	68.2 (65.2 , 71.0)	- (- , -)	78.2 (74.8 , 81.3)	54.8 (49.6 , 59.7)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	29,826	48.3 (47.5 , 49.0)	- (- , -)	60.8 (59.7 , 61.9)	38.8 (37.7 , 39.8)			
2(a) 2.9. Heavy chain disease	28	70.4 (43.2 , 86.3)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	7,407	67.3 (65.7 , 68.9)	92.1 (83.1 , 96.4)	76.2 (74.1 , 78.1)	61.2 (58.9 , 63.5)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2007-2013

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	10,802	65.4 (64.3 , 66.5)	86.2 (84.0 , 88.2)	69.4 (68.1 , 70.8)	50.9 (48.5 , 53.2)				
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	404	67.0 (62.1 , 71.5)	89.6 (84.4 , 93.2)	50.0 (42.2 , 57.3)	6.4 (0.6 , 23.3)				
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	10,359	65.4 (64.3 , 66.6)	85.4 (82.9 , 87.7)	70.2 (68.8 , 71.5)	51.4 (49.0 , 53.7)				
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,605	90.3 (88.2 , 92.1)	96.6 (76.7 , 99.6)	92.8 (90.7 , 94.4)	84.7 (79.2 , 88.8)				
2(b) 2.1.1. Mycosis fungoides	2,525	91.9 (89.8 , 93.6)	96.6 (76.7 , 99.6)	93.8 (91.7 , 95.3)	87.5 (81.7 , 91.5)				
2(b) 2.1.2. Sezary syndrome	80	37.6 (22.5 , 52.7)	- (- , -)	40.6 (19.5 , 60.8)	34.5 (14.2 , 56.0)				
2(b) 2.2. Peripheral T-cell lymphoma	5,693	57.5 (55.9 , 59.1)	83.5 (78.0 , 87.7)	66.0 (64.0 , 67.8)	42.5 (39.7 , 45.3)				
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,993	38.5 (35.8 , 41.1)	60.3 (42.7 , 74.0)	48.5 (44.9 , 51.9)	25.8 (21.9 , 29.8)				
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	749	40.7 (36.4 , 45.0)	- (- , -)	52.1 (45.6 , 58.1)	31.7 (25.9 , 37.6)				
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	74	89.2 (76.1 , 95.4)	- (- , -)	86.3 (70.5 , 94.0)	- (- , -)				
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,122	62.1 (58.7 , 65.4)	86.9 (80.1 , 91.5)	67.6 (63.5 , 71.3)	34.0 (26.4 , 41.7)				
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	53	20.8 (9.2 , 35.6)	- (- , -)	18.1 (5.8 , 35.8)	- (- , -)				
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	64	10.7 (3.5 , 22.5)	- (- , -)	- (- , -)	15.9 (4.3 , 34.1)				
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	1,126	84.4 (81.1 , 87.2)	96.3 (76.3 , 99.5)	88.2 (84.6 , 90.9)	77.5 (71.2 , 82.5)				
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	512	89.3 (84.1 , 92.8)	- (- , -)	94.6 (90.0 , 97.1)	78.7 (65.5 , 87.3)				
2(b) 2.3. Adult T-cell leukemia/lymphoma	1,359	63.6 (60.5 , 66.5)	85.2 (81.9 , 87.9)	46.1 (40.7 , 51.4)	18.6 (10.6 , 28.4)				
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	458	43.6 (38.1 , 48.9)	- (- , -)	44.4 (38.3 , 50.4)	37.5 (25.7 , 49.2)				
2(b) 2.5. T-cell large granular lymphocytic leukemia	78	70.4 (56.5 , 80.6)	- (- , -)	78.9 (61.9 , 89.0)	57.0 (34.4 , 74.4)				
2(b) 2.6. Prolymphocytic leukemia, T-cell	166	16.2 (9.1 , 25.1)	- (- , -)	21.0 (11.8 , 31.9)	9.2 (1.8 , 24.1)				
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	39	42.7 (26.6 , 57.8)	- (- , -)	- (- , -)	- (- , -)				
2(c) Non-Hodgkin lymphoma, unknown lineage	1,093	59.9 (56.5 , 63.1)	86.3 (81.2 , 90.1)	58.3 (52.8 , 63.3)	45.8 (40.3 , 51.2)				
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	445	64.5 (59.7 , 69.0)	86.4 (81.3 , 90.2)	44.7 (35.0 , 53.8)	22.9 (13.5 , 33.9)				
2(c) 2. Prolymphocytic leukemia, unknown lineage	39	50.3 (33.2 , 65.2)	- (- , -)	- (- , -)	41.5 (22.7 , 59.4)				
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	609	57.0 (52.2 , 61.5)	- (- , -)	64.5 (57.8 , 70.4)	50.8 (44.3 , 56.9)				
2(*) 1. Total precursor lymphoma/leukemia ^d	8,979	68.4 (67.3 , 69.5)	88.6 (87.6 , 89.6)	40.6 (38.4 , 42.7)	18.3 (15.1 , 21.8)				
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	148	72.5 (62.3 , 80.4)	- (- , -)	81.8 (70.4 , 89.2)	52.5 (32.0 , 69.5)				
4 Lymphoid neoplasm, NOS ^c	4,000	50.2 (48.3 , 52.2)	85.2 (75.4 , 91.3)	63.5 (60.6 , 66.1)	40.1 (37.3 , 42.8)				

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.30
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	99,036	69.6 (69.2 , 70.0)	89.9 (89.0 , 90.8)	76.0 (75.6 , 76.5)	59.1 (58.4 , 59.8)			
1 Hodgkin Lymphoma	8,117	85.6 (84.6 , 86.5)	96.3 (94.6 , 97.4)	88.8 (87.8 , 89.7)	56.6 (52.2 , 60.6)			
2 Non-Hodgkin lymphoma	88,734	68.6 (68.2 , 69.0)	88.4 (87.3 , 89.4)	74.6 (74.1 , 75.1)	59.7 (59.0 , 60.4)			
2(a) Non-Hodgkin lymphoma, B-cell	81,691	69.0 (68.5 , 69.4)	89.1 (87.9 , 90.2)	75.5 (75.0 , 76.0)	60.3 (59.5 , 61.1)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	4,401	68.3 (66.7 , 69.8)	88.3 (86.8 , 89.6)	38.4 (35.2 , 41.6)	17.4 (12.5 , 23.0)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	73,377	69.2 (68.7 , 69.7)	92.0 (89.6 , 93.9)	76.9 (76.4 , 77.5)	60.7 (59.9 , 61.5)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	19,315	78.2 (77.3 , 79.2)	- (- , -)	86.3 (85.2 , 87.3)	71.8 (70.3 , 73.2)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	16,568	81.7 (80.6 , 82.6)	- (- , -)	89.4 (88.2 , 90.4)	75.6 (74.0 , 77.1)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	63	52.9 (35.5 , 67.6)	- (- , -)	70.1 (44.5 , 85.6)	40.8 (20.3 , 60.3)			
2(a) 2.1.3. Mantle-cell lymphoma	2,684	57.3 (54.7 , 59.9)	- (- , -)	68.7 (65.2 , 71.9)	46.9 (42.9 , 50.8)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,680	80.6 (77.0 , 83.6)	- (- , -)	87.6 (83.3 , 90.9)	76.2 (71.0 , 80.6)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	732	77.5 (72.0 , 82.1)	- (- , -)	82.3 (75.1 , 87.7)	74.5 (66.5 , 80.9)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	948	83.0 (78.1 , 86.9)	- (- , -)	91.4 (85.4 , 95.0)	77.6 (70.3 , 83.2)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	18,768	62.3 (61.4 , 63.2)	91.2 (86.8 , 94.2)	69.9 (68.8 , 70.9)	52.5 (50.9 , 54.0)			
2(a) 2.3.1. DLBCL, NOS ^c	18,562	62.3 (61.3 , 63.2)	91.3 (86.8 , 94.3)	69.9 (68.9 , 71.0)	52.5 (51.0 , 54.1)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	28	35.8 (15.7 , 56.5)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	47	22.2 (9.1 , 38.8)	- (- , -)	18.4 (6.2 , 35.7)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	131	83.8 (73.3 , 90.4)	- (- , -)	85.1 (73.9 , 91.8)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	1,607	64.3 (61.6 , 66.9)	91.2 (87.5 , 93.8)	59.1 (55.7 , 62.3)	41.5 (32.9 , 49.9)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,449	89.1 (87.2 , 90.7)	100.0 (- , -)	92.2 (90.3 , 93.7)	85.4 (81.9 , 88.3)			
2(a) 2.5.1. Splenic MZL	386	85.4 (78.0 , 90.5)	- (- , -)	81.2 (72.1 , 87.6)	85.9 (77.0 , 91.6)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,649	94.0 (91.6 , 95.7)	100.0 (- , -)	95.3 (93.0 , 96.8)	92.2 (86.9 , 95.5)			
2(a) 2.5.3. Nodal MZL	1,414	80.6 (76.9 , 83.8)	- (- , -)	88.2 (84.2 , 91.2)	73.5 (67.5 , 78.6)			
2(a) 2.6. Follicular lymphoma	8,827	87.0 (85.8 , 88.1)	96.7 (77.2 , 99.6)	90.8 (89.6 , 91.8)	80.9 (78.5 , 83.2)			
2(a) 2.7. Hairy-cell leukemia	1,252	93.9 (91.0 , 95.9)	- (- , -)	96.4 (93.6 , 97.9)	86.4 (78.3 , 91.6)			
2(a) 2.8. Plasma cell neoplasms	17,461	49.5 (48.5 , 50.6)	- (- , -)	61.2 (59.8 , 62.6)	39.5 (38.0 , 40.9)			
2(a) 2.8.1. Plasmacytoma	1,199	68.5 (64.6 , 72.0)	- (- , -)	77.0 (72.6 , 80.7)	55.6 (48.3 , 62.3)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	16,262	48.1 (47.0 , 49.2)	- (- , -)	59.7 (58.2 , 61.1)	38.6 (37.1 , 40.1)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,913	66.2 (63.9 , 68.3)	92.9 (81.8 , 97.3)	73.5 (70.7 , 76.0)	59.8 (56.3 , 63.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	6,454	64.4 (62.9 , 65.8)	86.6 (83.9 , 88.8)	66.5 (64.7 , 68.3)	50.0 (46.7 , 53.1)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	282	66.4 (60.4 , 71.7)	88.6 (82.0 , 92.9)	47.2 (37.9 , 56.0)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	6,151	64.3 (62.7 , 65.8)	86.0 (83.0 , 88.6)	67.3 (65.4 , 69.1)	50.6 (47.3 , 53.8)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,472	88.3 (85.2 , 90.8)	100.0 (- , -)	90.8 (87.8 , 93.1)	81.6 (73.4 , 87.5)			
2(b) 2.1.1. Mycosis fungoides	1,422	90.1 (87.0 , 92.5)	100.0 (- , -)	91.9 (88.9 , 94.1)	85.1 (76.4 , 90.7)			
2(b) 2.1.2. Sezary syndrome	50	31.8 (13.4 , 51.9)	- (- , -)	- (- , -)	26.8 (5.3 , 55.5)			
2(b) 2.2. Peripheral T-cell lymphoma	3,330	56.1 (54.0 , 58.2)	82.9 (75.7 , 88.2)	62.8 (60.2 , 65.3)	42.4 (38.6 , 46.2)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,195	38.9 (35.5 , 42.4)	63.8 (41.9 , 79.3)	47.3 (42.7 , 51.7)	26.5 (21.4 , 31.9)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	411	35.8 (30.1 , 41.6)	- (- , -)	43.4 (34.9 , 51.5)	29.2 (21.3 , 37.5)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	30	87.0 (60.2 , 96.3)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	686	59.9 (55.5 , 64.1)	88.2 (79.7 , 93.3)	63.5 (58.1 , 68.4)	34.2 (24.6 , 44.0)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	38	21.8 (7.8 , 40.4)	- (- , -)	21.9 (5.6 , 45.0)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	32	12.6 (3.2 , 28.7)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	649	83.6 (78.9 , 87.4)	- (- , -)	86.9 (81.9 , 90.7)	76.6 (67.7 , 83.3)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	289	88.0 (80.6 , 92.7)	- (- , -)	93.8 (86.6 , 97.2)	78.2 (60.3 , 88.7)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	930	66.9 (63.2 , 70.3)	86.2 (82.5 , 89.2)	48.7 (42.2 , 54.8)	9.2 (1.1 , 28.6)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	296	42.9 (36.2 , 49.4)	- (- , -)	42.0 (34.3 , 49.4)	38.1 (23.6 , 52.5)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	31	62.8 (40.2 , 78.9)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	92	17.9 (8.5 , 30.1)	- (- , -)	19.6 (8.3 , 34.3)	14.5 (2.9 , 35.0)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	589	56.1 (51.5 , 60.5)	83.3 (75.7 , 88.8)	53.4 (46.5 , 59.8)	40.6 (32.2 , 48.7)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	249	60.5 (53.8 , 66.5)	82.9 (75.2 , 88.5)	38.4 (26.5 , 50.1)	25.0 (11.9 , 40.5)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	321	53.0 (46.5 , 59.1)	- (- , -)	59.7 (51.3 , 67.1)	44.1 (34.0 , 53.7)			
2(*) 1. Total precursor lymphoma/leukemia ^d	4,932	67.9 (66.4 , 69.3)	88.1 (86.7 , 89.4)	39.5 (36.6 , 42.4)	17.9 (13.3 , 23.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	85	78.9 (65.2 , 87.6)	- (- , -)	81.3 (68.0 , 89.5)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,100	48.8 (46.0 , 51.4)	84.7 (72.2 , 91.9)	58.6 (54.9 , 62.2)	38.6 (34.6 , 42.6)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	79,125	70.9 (70.5 , 71.3)	90.6 (89.5 , 91.6)	80.2 (79.7 , 80.7)	60.5 (59.8 , 61.2)			
1 Hodgkin Lymphoma	6,722	87.4 (86.4 , 88.4)	97.0 (95.4 , 98.0)	91.5 (90.5 , 92.4)	56.8 (52.4 , 61.0)			
2 Non-Hodgkin lymphoma	70,440	69.8 (69.3 , 70.2)	88.7 (87.3 , 89.9)	78.5 (78.0 , 79.1)	61.2 (60.5 , 61.9)			
2(a) Non-Hodgkin lymphoma, B-cell	65,588	70.0 (69.5 , 70.5)	89.2 (87.8 , 90.5)	79.0 (78.4 , 79.6)	61.7 (60.9 , 62.4)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,729	68.9 (67.2 , 70.6)	89.1 (87.5 , 90.5)	40.3 (36.8 , 43.9)	18.6 (13.8 , 23.9)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	58,365	70.2 (69.6 , 70.7)	89.8 (85.9 , 92.7)	80.6 (80.0 , 81.2)	62.1 (61.3 , 62.9)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	12,321	80.5 (79.3 , 81.7)	- (- , -)	88.9 (87.5 , 90.1)	75.9 (74.2 , 77.6)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	11,170	82.7 (81.5 , 83.9)	- (- , -)	91.1 (89.7 , 92.3)	78.1 (76.3 , 79.8)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	27	47.0 (24.9 , 66.4)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.1.3. Mantle-cell lymphoma	1,124	59.3 (55.2 , 63.2)	- (- , -)	68.9 (62.9 , 74.2)	53.6 (47.9 , 58.9)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,213	82.9 (79.0 , 86.1)	- (- , -)	90.1 (85.8 , 93.2)	78.5 (72.9 , 83.1)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	582	77.3 (71.5 , 82.0)	- (- , -)	86.0 (78.7 , 90.9)	72.0 (63.8 , 78.7)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	631	87.6 (82.2 , 91.5)	- (- , -)	93.3 (87.6 , 96.5)	83.8 (75.6 , 89.5)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,405	62.3 (61.3 , 63.3)	87.2 (81.2 , 91.4)	75.1 (73.8 , 76.3)	52.3 (50.8 , 53.7)			
2(a) 2.3.1. DLBCL, NOS ^c	15,151	61.9 (60.9 , 62.9)	88.1 (82.0 , 92.3)	74.6 (73.3 , 75.9)	52.3 (50.8 , 53.7)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	33	61.3 (40.2 , 76.9)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	217	89.3 (83.6 , 93.2)	- (- , -)	91.3 (85.6 , 94.9)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	637	57.6 (53.2 , 61.8)	91.2 (84.2 , 95.2)	56.8 (50.8 , 62.4)	35.5 (27.8 , 43.2)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	5,157	90.7 (89.1 , 92.1)	- (- , -)	94.7 (93.1 , 95.9)	87.3 (84.5 , 89.6)			
2(a) 2.5.1. Splenic MZL	455	82.7 (76.0 , 87.7)	- (- , -)	87.0 (78.6 , 92.3)	79.2 (68.5 , 86.6)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	3,212	94.9 (92.9 , 96.3)	- (- , -)	96.8 (95.1 , 97.9)	92.8 (88.8 , 95.4)			
2(a) 2.5.3. Nodal MZL	1,490	84.2 (80.9 , 86.9)	- (- , -)	91.4 (87.6 , 94.1)	78.8 (73.7 , 83.0)			
2(a) 2.6. Follicular lymphoma	8,993	88.3 (87.2 , 89.4)	- (- , -)	93.8 (92.8 , 94.7)	81.8 (79.6 , 83.7)			
2(a) 2.7. Hairy-cell leukemia	310	90.5 (82.9 , 94.8)	- (- , -)	97.3 (92.4 , 99.0)	75.8 (57.9 , 86.9)			
2(a) 2.8. Plasma cell neoplasms	14,319	49.4 (48.3 , 50.5)	- (- , -)	63.5 (61.9 , 65.1)	39.6 (38.0 , 41.1)			
2(a) 2.8.1. Plasmacytoma	755	67.6 (62.8 , 72.0)	- (- , -)	80.3 (74.3 , 85.1)	52.9 (45.5 , 59.8)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	13,564	48.4 (47.2 , 49.5)	- (- , -)	62.4 (60.7 , 64.0)	38.9 (37.4 , 40.4)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,494	68.5 (66.2 , 70.7)	- (- , -)	80.0 (77.0 , 82.7)	62.4 (59.2 , 65.4)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	4,348	67.0 (65.2 , 68.7)	85.2 (80.7 , 88.7)	73.8 (71.7 , 75.8)	52.0 (48.6 , 55.2)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	122	68.4 (59.0 , 76.1)	92.4 (80.9 , 97.1)	56.3 (41.9 , 68.4)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	4,208	67.1 (65.2 , 68.8)	83.8 (78.5 , 87.9)	74.5 (72.3 , 76.4)	52.4 (49.0 , 55.7)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,133	92.6 (89.6 , 94.8)	93.2 (59.7 , 99.0)	95.3 (92.2 , 97.2)	87.6 (79.8 , 92.5)			
2(b) 2.1.1. Mycosis fungoides	1,103	93.9 (90.8 , 96.0)	93.2 (59.7 , 99.0)	96.1 (93.0 , 97.8)	89.7 (81.4 , 94.4)			
2(b) 2.1.2. Sezary syndrome	30	42.4 (21.4 , 62.0)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2. Peripheral T-cell lymphoma	2,363	59.4 (57.0 , 61.7)	84.2 (74.4 , 90.5)	70.7 (67.7 , 73.5)	42.3 (38.3 , 46.4)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	798	37.7 (33.6 , 41.9)	- (- , -)	50.2 (44.3 , 55.8)	24.8 (19.1 , 30.9)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	338	45.9 (39.5 , 52.1)	- (- , -)	63.6 (54.0 , 71.7)	33.9 (25.7 , 42.2)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	44	90.5 (73.5 , 96.8)	- (- , -)	85.0 (63.1 , 94.4)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	436	65.5 (60.1 , 70.4)	84.0 (70.0 , 91.8)	73.8 (67.3 , 79.3)	33.1 (22.5 , 44.2)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	32	7.7 (0.7 , 26.3)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	477	85.2 (80.1 , 89.1)	- (- , -)	89.9 (84.6 , 93.5)	77.2 (66.5 , 84.9)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	223	90.8 (82.3 , 95.4)	- (- , -)	95.2 (88.1 , 98.1)	79.4 (56.4 , 91.2)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	429	56.0 (50.0 , 61.6)	82.1 (74.6 , 87.5)	40.6 (30.4 , 50.5)	23.9 (12.9 , 36.7)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	162	44.5 (34.8 , 53.7)	- (- , -)	48.8 (38.6 , 58.3)	37.1 (18.8 , 55.5)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	47	74.8 (56.1 , 86.4)	- (- , -)	80.1 (58.5 , 91.3)	- (- , -)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	74	13.3 (4.5 , 26.9)	- (- , -)	22.1 (8.8 , 39.2)	7.0 (0.5 , 26.4)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	504	64.3 (59.2 , 68.9)	89.8 (82.3 , 94.3)	66.8 (57.8 , 74.4)	49.0 (41.5 , 56.2)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	196	69.6 (62.3 , 75.8)	90.6 (83.2 , 94.9)	53.7 (38.0 , 67.1)	19.3 (7.8 , 34.7)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	288	61.2 (54.2 , 67.4)	- (- , -)	73.9 (62.3 , 82.4)	54.1 (45.3 , 62.0)			
2(*) 1. Total precursor lymphoma/leukemia ^d	4,047	69.0 (67.4 , 70.6)	89.3 (87.8 , 90.6)	42.0 (38.6 , 45.2)	18.7 (14.3 , 23.6)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	63	62.1 (44.7 , 75.4)	- (- , -)	82.0 (58.0 , 93.0)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	1,900	51.9 (49.0 , 54.8)	86.4 (66.7 , 94.8)	70.5 (66.2 , 74.3)	41.4 (37.6 , 45.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).


^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Figure 19.1

SEER Observed Incidence, SEER Delay Adjusted Incidence and US Death Rates^a Non-Hodgkin Lymphoma, by Race and Sex



Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC).

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute.

The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.


* The APC is significantly different from zero ($p < 0.05$).

Figure 19.2

SEER Incidence and US Death Rates^a Non-Hodgkin Lymphoma, Both Sexes

Joinpoint Analyses for Whites and Blacks from 1975-2014

and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2014



Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2014 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2014 allow a maximum of 4 joinpoints.


^b API = Asian/Pacific Islander.

^c AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^d Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from New Hampshire and Oklahoma.

Figure 19.3


Non-Hodgkin Lymphoma Incidence Rates, 1980 vs 2014 Males by Age at Diagnosis and SEER area



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103).

Figure 19.4


Non-Hodgkin Lymphoma SEER Incidence by Age 1975-1977 vs 2012-2014 All Races, Males



Source: SEER 9 areas. Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103).

Figure 19.5

SEER Observed Incidence and SEER Delay Adjusted Incidence Rates^a SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Male, by Race




● SEER 9 Delay-Adj. Incidence
 ○ SEER 9 Observed Incidence
 ■ SEER 13 Delay-Adj. Incidence
 □ SEER 13 Observed Incidence

Source: SEER 9 areas and SEER 13 areas.
^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute.
 The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
 * The APC is significantly different from zero (p < 0.05).

Figure 19.6

SEER Observed Incidence and SEER Delay Adjusted Incidence Rates^a SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Female, by Race




● SEER 9 Delay-Adj. Incidence
 ○ SEER 9 Observed Incidence
 ■ SEER 13 Delay-Adj. Incidence
 □ SEER 13 Observed Incidence

Source: SEER 9 areas and SEER 13 areas.
^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.4, January 2017, National Cancer Institute.
 The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
 * The APC is significantly different from zero ($p < 0.05$).

Figure 19.7

Non-Hodgkin Lymphoma 5-Year SEER Conditional Relative Survival and 95% Confidence Intervals

Probability of surviving the next 5 years given the cohort
has already survived 0, 1, or 3 years
1998-2013 by stage at diagnosis



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG contribute cases for diagnosis years 2000 and later. The remaining 13 SEER Areas contribute cases for the entire time period. Percent surviving is not shown if based on less than 25 cases. Confidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error.